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1.1. Breast cancer incidence and mortality rates 
1.1.1. Rates worldwide 
Breast cancer (BC) is the most common cancer in women worldwide, accounting for 
11.6% of all cancers (Bray et al., 2018). According to GLOBOCAN (2018), it was 
estimated that 2.09 million new BC cases were diagnosed. Among the cases, 
508,420 were attributed to countries with low and medium human development index 
(HDI), while 1,579,200 of them were attributed to countries with high and very high 
HDI. Age-standardized incidence rates in women vary nearly four-fold across the 
world regions, with rates ranging from 25.9 per 100,000 in South-Central Asia to 94.2 
per 100,000 in Australia and New Zealand (Figure 1). 
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Figure 1: Estimated age-standardized breast cancer incidence rates worldwide in 2018 (Extracted 
from Globocan 2018). 
GLOBOCAN (2018) reported that 626,679 deaths were due to BC in the world in 
2018, ranking BC as the fifth cause of death from cancer overall. The variation in 




more favorable survival of BC in (high-incidence) developed regions (Ghoncheh et 
al., 2016), with rates ranging from 8.6 per 100,000 in Eastern Asia to 25.5 per 
100,000 in Melanesia (Figure 2). 
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Figure 2: Estimated age-standardized breast cancer mortality rates worldwide in 2018 (Extracted from 
Globocan 2018). 
The BC mortality to incidence ratio (MIR) computed by dividing the mortality rate by 
the incidence rate is another means to assess the burden of a diseases (Choi et al., 
2017). Less developed countries tend to have higher MIRs of BC compared to 
developed countries. For example, in Colombia the MIR is 0.27, while the MIR in 
United States is 0.15 and those in Western Europe countries are in the range of 0.14 
and 0.19. High MIR indicates low survival. This could be due to late stage at 





1.1.2. Rates in Latin America 
BC is a major public health problem and the main cause of cancer related death 
among Latin Americans and Caribbean women, with an estimated 199,734 women 
diagnosed in 2018, representing 9.6% of all BC cases worldwide (Bray et al., 2018).  
Across Latin American and the Caribbean countries, a heterogeneous distribution of 
the estimated incidence rates, with values ranging from 23.6 to 78.3 per 100,000 
women, is observed. The highest incidence rates in these countries were found in 
Argentina and Puerto Rico, with 78.3 and 73.0 per 100,000 women, respectively. 
Intermediate rates have been observed in Colombia with 44.1 per 100,000 women, 
whereas the lowest incidence rates were found in Haiti, Guatemala, and Bolivia 
(23.6, 26.2, and 26.5 per 100,000 women, respectively) (Bray et al., 2018). 
Similar to the incidence rates, the estimated mortality rates also vary considerably 
according to country, with values from 7.3 to 33.1 per 100,000 women. The highest 
mortality rates are observed in Dominican Republic with 26.1 per 100,000 women. In 
Colombia, the mortality rate is 11.9 per 100,000 women (Bray et al., 2018).  
The BC MIR in the Latin American and Caribbean countries are also variable. For 
every 100 women diagnosed with BC, 25 will die of the disease in Mexico, whereas 
31 and 61 will die in Guyana and Haiti, respectively. 
Figure 3 shows the cumulative probability of BC incidence and mortality rate between 
1980 and 2010 for individuals aged 15-79 years in some Latin American countries. A 
very high cumulative incidence of BC (more than 8% of cumulative probability) is 
observed in Uruguay and Argentina. By contrast, El Salvador shows a cumulative 





Figure 3: Cumulative probability of breast cancer incidence and mortality in Latin American countries. 
(A) Cumulative probability of breast cancer incidence increase over time. (B) Cumulative probability of 
breast cancer mortality varies across countries. Data extracted from Table 2 and Table 4 (Forouzanfar 
et al., 2011). 
An increase in the incidence and mortality rates was observed in some Latin 
American countries (Forouzanfar et al., 2011). For example, in Colombia the 
cumulative probability of BC for women was 2.6 (2.3–3.8) in 1980 and 4.2 (3.6–5.0) 
in 2010 (Figure 3). A similar increase was observed in the mortality rate, which was 
1.2 (1.1–1.7) in 1980 and 1.4 (1.2–1.6) in 2010. 
The absolute number of cases and deaths has risen among Latin American and 
Hispanic women. This is probably due to the rising population numbers of women 
around the time of the menopause, together with the late stage at diagnosis (Pineros 






1.2. Classification of breast cancer  
BC is a heterogeneous disease due to its diverse pathological features, variable 
clinical outcome, and response to treatments (Viale, 2012). 
The histopathological classification of breast tumors is based on several 
morphological tumor features. It can be classified into several categories, ranging 
from benign, carcinoma in situ to invasive carcinoma, and sarcoma (Sinn and Kreipe, 
2013). Breast carcinoma in situ, characterized by the proliferation of cancer cells 
within the epithelial tissue without invasion of the surrounding tissue can be further 
classified as either ductal or lobular (Malhotra et al., 2010). Invasive breast tumors 
are characterized by invasion of tumor cells in adjacent tissues and can be further 
separated in several categories based on their histological morphology, location, and 
structure. Invasive ductal carcinoma is the most common subtype representing 75% 
of all BCs, followed by invasive lobular carcinoma, which represents about 10% of all 
BCs (Li et al., 2005; Weigelt et al., 2008). The remaining BCs distribute in various 
other rare subtypes, such as medullary, tubular, mucinous, apocrine, 
neuroendocrine, inflammatory, metaplastic, comedo, adenoid cystic, and 
macropapillary subtypes (Dieci et al., 2014; Weigelt et al., 2008). 
In clinical practice, breast tumors are routinely classified in at least three main 
subtypes on the basis of immunohistochemistry: estrogen receptor 
(ER)/progesterone receptor (PR) positive (ER+/PR+), epidermal growth factor 
receptor 2 (HER-2) positive (HER-2+), and triple negative (ER-/PR-/HER-2-). 
Breast tumors can also be classified by gene expression profiling analyzed by cDNA 
microarrays and hierarchical clustering. This led to the identification of five intrinsic 
molecular subtypes: luminal A (ER+, PR+, Ki-67 low), luminal B (ER+, PR+, Ki-67 




subtypes associate with different clinical prognosis. Luminal A and ER+/PR+ 
subtypes generally associate with a better prognosis, while basal, ER-/PR-, and 
BRCA1-associated tumors are linked with a worse prognosis (Dai et al., 2015). The 
determination of the molecular subtype is of importance for treatment decisions. 
Detailed genetic and clinical response of BC to hormonal therapy has not been 
systematically taken into account in BC studies in Latin America and among Hispanic 
populations. A study conducted among 301 patients from Colombia reported a 
prevalence of 37.2% for luminal B BCs, 26.3% for luminal A BCs, 11.6% for non-
basal triple negative BCs (TNBCs), 9% for basal like tumors, 8.6% for HER-2+ 
tumors, and 69.1% for ER+ tumors (Serrano-Gomez et al., 2016). In Europeans 
countries a prevalence of 6%-12.5% is observed for luminal B BCs, 68.7%-75% for 
luminal A BCs, 11.8%-12% for TNBCs, and 3%-8% for HER-2+ tumors (Awadelkarim 
et al., 2008; Elidrissi Errahhali et al., 2017; Puig-Vives et al., 2013; Yang et al., 2007). 
1.3. Risk factors associated with breast cancer 
BC is a complex disease with many non-genetic and genetic risk factors contributing 
to its development. 
1.3.1. Non-genetic risk factors 
Non-genetic risk factors of BC are conditioned by lifestyle, age or long-term medical 
intervention such as use of oral hormonal contraceptives. As many other cancers, 
age is one of the strongest risk factors for BC. It has been reported that BC incidence 
for women doubles about every 10 years, reaching an incidence of 500 cases per 
100,000 woman-years at age 70 (Baselga and Norton, 2002). Age of diagnosis is 
variable worldwide and Latin American women have a high risk of developing BC at 




Colombian BC cases occur in women younger than 45 years, in contrast to 12% in 
higher-income countries (Franco-Marina et al., 2015). 
Reproductive factors are associated with BC risk and are partly responsible for the 
diverse distribution of BC. First full-term pregnancy after 30 years of age, never 
having children, and lack of breastfeeding increase BC risk. On the other hand, 
multiparous women with more than five children had a reduced risk of BC 
(Collaborative Group on Hormonal Factors in Breast, 2002; Kelsey et al., 1993). In a 
hospital case-control study carried out in Bogota, parous women who had breastfed 
their first child had a reduced BC risk (P-value = 0.001). Compared with women with 
more than three children, nulliparous women had an OR of 3.35 (95% CI 1.40-8.0, P-
value = 0.001) (Olaya-Contreras et al., 1999).  
Early menarche and late menopause are known to increase women´s risk of 
developing BC (Collaborative Group on Hormonal Factors in Breast, 2012). A study 
among 3,993 BC cases and 11,783 controls demonstrated that a delay of two years 
in the age at menarche corresponds to a 10% reduction in BC risk (Hsieh et al., 
1990).  
Passive and active smoking habits have also been linked to an increased risk of BC 
in younger, primarily premenopausal women (Bottorff et al., 2010; Johnson, 2005). 
There is some evidence for a link between heavy second-hand smoke exposure and 
BC risk in postmenopausal women (Johnson, 2005). 
The use of oral contraceptives and menopausal hormonal therapy, especially 
combined estrogen and progestin therapy, may also increase the risk of BC 
(Collaborative Group on Hormonal Factors in Breast, 1996; Tavassoli FA, 2003). 




estrogen therapy with longer duration of use in current and recent users (Tavassoli 
FA, 2003). 
Higher body mass index (BMI) increases BC risk among postmenopausal women 
and the association appears to increase with advancing age after menopause 
(Tavassoli FA, 2003). Several studies have shown that obese pre- and 
postmenopausal women with BC have a poor survival and tend to have tumors of 
larger size (Cuello-Lopez et al., 2017; Eichholzer et al., 2012; Ioannides et al., 2014; 
Kann et al., 2014; Niraula et al., 2012; Renehan et al., 2008). In Colombian BC 
patients, 34.28% are overweight and 28.15% suffer from obesity. Higher BMI among 
premenopausal women was associated with hormone receptor negative tumors (i.e 
ER-/PR-) and greater lymphovascular invasion (Cuello-Lopez et al., 2017). 
1.3.2. Genetic risk factors 
1.3.2.1. Genetic ancestry and family history of breast cancer 
Differences in race and ethnicity may contribute to variation of BC incidence across 
populations. Caucasian women have higher age adjusted BC incidence rates than 
most African, Asian, and Latin American women.  
Although incidence of BC is higher in Caucasian women, sub-Saharan African and 
African-American women are more likely to be diagnosed with biologically aggressive 
phenotypes like TNBC and have higher BC mortality rates (Jiagge et al., 2018; 
Jiagge et al., 2016; Newman and Kaljee, 2017). 
In Asia, BC is the most common cancer. The incidence rate is low compared to other 
regions, but it is increasing rapidly. Asian women tend to have children at younger 
ages than in the west and the age-specific incidence decreases for women over 50 




The variation in incidence can be noticed not only worldwide, but also between ethnic 
groups within countries. In a previous study among Latina women in the San 
Francisco Bay Area it was shown that Latinas have incidence rates that are 35% 
lower than the rates of Caucasian women (Ziv et al., 2006).  
The term Hispanic and Latino describe a heterogeneous population. Compared to 
others populations they have a more complex genetic background representing a mix 
of Native American, European, and African ancestries (Fejerman et al., 2010). 
Among US Latina women, those with a high proportion of Native American ancestry 
are at a lower risk of developing BC and those with higher European ancestry have 
an increased risk of BC (Fejerman et al., 2012; Fejerman et al., 2010; Ziv et al., 
2006).  
Hereditary BC comprises about 5% to 10% of all BC diagnosis worldwide (Society, 
2014). Along with genetic ancestry, the family history of BC contributes to the risk of 
developing the disease (Jiang et al., 2012; Phipps et al., 2011). In a meta-analysis 
published in 1997, Pharoah et al. reported that the magnitude of the risk of BC 
depends on the type of relative affected, the age at which the relative developed 
cancer, and the number of affected members (Pharoah et al., 1997). Compared to 
individuals with no family history of BC, the risk of BC doubles for women with first 
degree relatives (mother, sister, or daughter) who have been diagnosed with BC at 
50 years of age or older, and increased if the first-degree relative developed BC 
before 50 years of age. The relative risk associated with having a second-degree 
relative with BC was 1.5 (95% CI 1.4-1.6). Increasing numbers of affected first 
degree family members also increased the BC risk. Recently, first degree family 




(Collaborative Group on Hormonal Factors in Breast, 2001; Jiang et al., 2012; 
Pharoah et al., 1997; Phipps et al., 2011; Singletary, 2003; Society, 2017). 
1.3.2.2. Susceptibility genes and loci for breast cancer 
Genome-wide association studies (GWASs) have led to the identification of several 
BC susceptibility genes and loci that contribute to the familial risk. Up to 20% of the 
familial relative risk is due to rare mutations in high-penetrance genes including 
BRCA1, BRCA2, PTEN, TP53, CDH, and STK11. Mutations in these genes have a 
less than 0.1% risk allele frequency in the general population and confer a relative 
risk of up to 8 per risk allele (Figure 4). The high-penetrance genes confer a lifetime 
risks of BC up to 50% (Ghoussaini et al., 2013).  
 
Figure 4: Breast cancer susceptibility loci and their relative risk per risk allele and frequency 
(Extracted from (Garcia-Closas and Chanock, 2008)). 
Between 2% to 3% of cases are due to a mutation in moderate-penetrance genes, 
such as CHEK2, BRIP1, ATM, and PALB2, each associated with a two-fold increase 




associated with small increases in risk with relative risk less than 2 and a frequency 
of the risk allele higher than 20%. Low-penetrance alleles confer a lifetime risk in the 
range of 10% to 20% (Beggs and Hodgson, 2009; Garcia-Closas and Chanock, 
2008; Ghoussaini et al., 2013; Shiovitz and Korde, 2015). 
High-penetrance mutations 
High-penetrance mutations in TP53 are associated with the Li–Fraumeni syndrome, 
mutations in PTEN with the Cowden syndrome, and in STK11 with the Peutz–
Jeghers syndrome. CDH1 predispose to familial diffuse gastric cancer and BRCA1 
and BRCA2 mutations to breast and ovarian cancer (Beggs and Hodgson, 2009; 
Campeau et al., 2008; Garcia-Closas and Chanock, 2008).  
The most common cause of hereditary BC is an inherited mutation in the BRCA1 or 
BRCA2 gene. BRCA1 gene is located on chromosome 17 (locus: 17q12-q21). Its 
tumor suppressor role makes it crucial for genomic stability, DNA repair, DNA 
damage response, cell cycle checkpoint control, chromatin remodeling, 
transcriptional regulation, and protein ubiquitination (Hall et al., 1990; Narod and 
Foulkes, 2004). The BRCA2 gene was cloned in 1995. It is located on chromosome 
13q12-q13 (Wooster et al., 1995). BRCA2 plays an important role in homologous 
recombination, both in meiosis and repair of double-strand breaks (Thorslund and 
West, 2007). Mutations in BRCA2 are associated with an increased risk of ductal and 
lobular cancers, while BRCA1 mutations are frequently associated with invasive 
ductal carcinoma (Dossus and Benusiglio, 2015). Up to 15% of TNBCs have been 
associated with BRCA1 and BRCA2. TNBC accounts for 70% of breast tumors 
arising in BRCA1 mutation carriers and 16-23% of breast tumors in BRCA2 carriers 




Cancer Genome Atlas (TCGA) program showed that around twenty percent of basal-
like breast tumors have an inherited or somatic BRCA1 or BRCA2 mutation (Ling et 
al., 2016). 
Different studies on the BRCA1 and BRCA2 genes have been conducted in 
Colombia. These studies showed that BRCA1 and BRCA2 mutations affect between 
5% and 8% of unselected Colombian BC patients (Torres et al., 2017; Torres et al., 
2007). Among unselected BC cases, four founder mutations were identified: A1708E 
and 3450del4 in BRCA1 and 3034del4 and 1991del4 in BRCA2 (Torres et al., 2017). 
The cumulative risk of BC by age 70 years for Colombian women carrying a mutation 
in the BRCA1 gene was 14% (95% CI 5–38) and 3% for the general population 
(relative risk of BC 4.05) (Torres et al., 2017). In another report, Hernández et al. 
(Hernandez et al., 2014) assessed the prevalence of BRCA1/2 mutations in BC 
cases unselected for family history from Medellin. Among 244 patients, three (1.2%) 
deleterious mutations were identified: two in BRCA1, the same BRCA1 founder 
mutations as identified in the Colombian study (Torres et al., 2017) and one in 
BRCA2. 
Moderate-penetrance variants 
The variants in ATM, CHEK2, BRIP1, BARD1, and PALB2 have a contribution to 
familial risk less than 3%, due to the modest relative risk and relatively low frequency 
of the risk allele. These genes act in the same DNA repair pathways as BRCA1 and 
BRCA2, however, they confer less risk of breast and ovarian cancer (Figure 4) 







Mutations in high-risk BC genes such as BRCA1 and BRCA2 affect only small 
numbers of women, whereas variation in lower-impact, common susceptibility loci or 
single nucleotide polymorphisms (SNPs) can be responsible for a larger percentage 
of cancers in the population (Howell et al., 2014). The relative risks of common 
variants are small, but in combination can be associated with substantial increases or 
decreases in risk. The combination of risks of common variants can be measured 
through a polygenic risk score. A polygenic risk score gives a risk percentile of 
individual genetic predisposition to specific diseases and can be used to stratify 
women in the general population at different levels of risk of developing BC 
(Torkamani et al., 2018).  
Recently, about 170 common low-penetrance variants that cumulatively explain 18% 
of the familial relative risk have been identified in collaborative GWASs for individuals 
of European descent (Amos et al., 2017; Michailidou et al., 2015; Michailidou et al., 
2013; Michailidou et al., 2017). 
Despite the enormous progress in the discovery of novel BC susceptibility genes in 
the European population, only a few of the associations have been subsequently 
replicated in Latin American and Hispanic women (Fejerman et al., 2014; Fejerman 
et al., 2013; Slattery et al., 2011).  
Objectives and aims  
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2. Objectives and Aims 
BC is the main cause of cancer-related death among Colombian women. Its 
incidence is increasing and early diagnosis and strategies for cancer prevention 
remain unresolved problems. Only a few studies have been conducted in Latinas and 
Hispanic populations outside of the United States, and most strategies for BC 
prevention are based on women of European descent.  
The objective of this dissertation was to develop effective BC risk prediction models 
considering the characteristics of the Colombian population, taking advantage of 
individual genetic ancestry, information on established susceptibility factors, and 
recently identified common variants. The relevance of 78 BC susceptibility variants 
previously shown to be associated with BC risk in large-scale genetic association in 
European women to Colombian BC was examined and possible interactions with 
genetic ancestry were assessed. Study participants were women participating in the 
Colombian BC case-control study (Col-BCCC). 
The specific objectives of the research project were: 
 To quantify ancestry proportions in each woman and assess the relationship 
between ancestry and BC risk 
 To determine associations between genetic risk variants and BC risk, subtype 
specific risk and quantify the variance in BC liability due to susceptibility 
variants  
 To assess interactions between common variants and genetic ancestry on  
BC susceptibility  
 To build a multifactorial risk score (MRS) for BC risk prediction 
 
Materials and Methods  
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3. Materials and Methods 
3.1. Study populations 
The study population included 1,022 BC patients unselected for family history and 
age at BC diagnosis, and 1,023 healthy controls who participated in the Col-BCCC 
study. The Ethics Committee of the Pontificia Universidad Javeriana in Bogota 
approved the research protocol. All study participants signed the informed consent.  
The majority of cases were recruited in the period of 03/2007 to 02/2011 from 
hospitals located in the center of Colombia (Bogota, Neiva and Villavicencio). BC 
cases were diagnosed after January 1st, 2004. Controls were healthy and unrelated 
women recruited during the period 06/2007 to 06/2011. Controls reported no family 
history of any type of cancer in two generations and participated in the Colombian 
National Pap Smear Program (Pineros et al., 2007). Cases and controls were of 
Hispanic origin and matched by 2-year age classes. They were eligible if they resided 
in the study region.  
Table 1 provides information on established and potential BC risk factors that was 
collected from all study participants: age of diagnosis for cases and age at interview 
for controls, family history of BC in first-degree female relatives (yes / no), oral 
contraceptive use (yes / no), menopausal status and hormone therapy 
(premenopausal and postmenopausal never-hormone therapy, postmenopausal 
ever-hormone therapy), BMI (<25 / 25 to 29.9 / >=30 kg/m2), current smoking (never 
/ former / current), parity (nulliparous,1 to 2, ≥3 children), age at first full-term 
pregnancy (<20, 20 to 29, ≥30 years), age at menarche (≥14 / 12 to 13 / <12 years), 
and breastfeeding (Never / ≤12 / >12 months). 
  
Materials and Methods  
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Table1: Baseline characteristics of the study population 
Variable Level Cases N (%) Controls N (%) P-value1 
Age (years)  1,021 (99.90) 1,023 (100.00) 0.96 
Family history of breast 
cancer in first-degree female 
relatives 
No 770 (75.34) 921 (90.03) <0.0001 
Yes 
246 (24.07) 79 (7.72)  
Oral contraceptive use No 687 (67.22) 742 (72.53) 0.03 
Yes 310 (30.33) 270 (26.39)  





never used hormone 
therapy  894 (87.48) 972 (95.01) <0.0001 
Postmenopausal women 
who ever used hormone 
therapy  104 (10.18) 43 (4.20)  
Body mass index (kg/m2) <25   494 (48.34) 444 (43.40) 0.13 
25-29.9  366 (35.81) 388 (37.93)  
≥30   113 (11.06) 127 (12.41)  
Smoking status Never 684 (66.93) 775 (75.76) 0.0004 
Former 251 (24.56) 186 (18.18)  
Current 65 (6.36) 57 (5.57)  
Parity Nulliparous 158 (15.46) 118 (11.53) 0.002 
1-2 478 (46.77) 439 (42.91)  
≥3 377 (36.89) 440 (43.01)  
Age at first full-term 
pregnancy (years) 
<20 176 (17.22) 208 (20.33) 0.0002 
20-29 490 (47.95) 545 (53.27)  
≥30 178 (17.42) 119 (11.63)  
Age at menarche (years) ≥14 379 (37.08) 406 (39.69) 0.45 
12-13 463 (45.30) 447 (43.70)  
<12 155 (15.17) 144 (14.08)  
Breastfeeding (months) Never 219 (21.43) 158 (15.44) 0.0002 
≤12 296 (28.96) 264 (25.81)  
>12 468 (45.79) 546 (53.37)  
1P-values from two-sided chi-square test and smaller than 0.05 are marked in bold. 
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3.2. Selection of genetic variants and genotyping analysis 
Thirty markers highly informative for continental ancestry information (Ruiz-Linares et 
al., 2014) were selected for genotyping analysis. The ancestry informative markers 
(AIMs) were genotyped using the KASP allelic discrimination method (LGC 
Genomics). The sample set consisted of 1,757 native DNA samples and 288 Whole 
Genome Amplified (WGA) DNA samples. Cluster plots and genotypes were 
evaluated by the SNPviewer2 software version 4.0.0 (LGC Genomics). In addition, 
the clustering of intensity plots for AIMs with a P-value for Hardy-Weinberg 
equilibrium (HWE) departure among controls under 0.005 was visually inspected. 
The genotype concordance between WGA amplified DNA and native DNA was 
>99%. AIM call rates were ≥98.9% and the concordance rate of 122 DNA duplicates 
(6.0%) was 100%. Eight AIMs deviated from HWE in controls but corresponding 
intensity plots revealed clear genotype clusters. 
Seventy eight common BC susceptibility variants were selected for genotyping 
analysis (Table 2). They included 60 single nucleotide polymorphisms (SNP, 38 
novel and 22 previously known) associated with BC risk at genome-wide significance 
in a large European GWAS (Michailidou et al., 2013), 10 SNPs identified in fine-
mapping studies (Bojesen et al., 2013a; French et al., 2013a; Ghoussaini et al., 
2014; Meyer et al., 2013; Orr et al., 2015a; Udler et al., 2010a), 4 SNPs from a 
GWAS on ER- BC (Garcia-Closas et al., 2013a), 2 SNPs from a GWAS on 
postmenopausal BC (Hunter et al., 2007b), 1 SNP associated with BC risk in a 
postmenopausal case-control study but not in a GWAS study (Easton et al., 2007a; 
Prentice et al., 2009b), and 1 SNP from a GWAS on BRCA1-associated BC 
(Antoniou et al., 2010a). DNA samples from 1,022 BC patients and 1,023 healthy 
controls were genotyped using three different methods. Seventy-five SNPs were 
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analyzed by matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) (Sequenom, San Diego, CA, USA). SNP rs4808801 
was analyzed using KASP genotyping chemistry. Cluster plots and genotypes were 
evaluated by the SNPviewer2 software version 4.0.0 (LGC Genomics). Two SNPs - 
rs11552449_C>G and rs2736108_C>T were genotyped by TaqMan allelic 
discrimination using 20x TaqMan® SNP Genotyping Assays (assay ID 
C_25619066_10 and C_26414910_20, respectively) (ThermoFisher Scientific Inc., 
USA). SNP call rates were between 97.5% and 100%, the concordance rate of 119 
duplicates (5.8% of total samples) was >99% and the distribution of all genotypes 
met HWE in the control group. Genotyped variants, their location, gene/nearest 
gene(s), and genotyping methods are listed in Table 2. 
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Table 2: Genotyped variants, their location, gene/nearest gene(s), and genotyping 
methods 





Reference (Initial study) 
1 rs11249433 1p11.2 EMBP1 MALDI-TOF MS (Thomas et al., 2009) 
2 rs11552449 1p13.2 DCLRE1B TaqMan assay (Michailidou et al., 2013) 
3 rs616488 1p36.22 PEX14 MALDI-TOF MS (Michailidou et al., 2013) 
4 rs6678914 1q32.1 LGR6 MALDI-TOF MS (Garcia-Closas et al., 2013b) 
5 rs4245739 1q32.1 MDM4 MALDI-TOF MS (Garcia-Closas et al., 2013b) 
6 rs12710696 2p24.1 OSR1 MALDI-TOF MS (Garcia-Closas et al., 2013b) 
7 rs4849887 2q14.1 INHBB MALDI-TOF MS (Michailidou et al., 2013) 
8 rs1550623 2q31.1 CDCA7 MALDI-TOF MS (Michailidou et al., 2013) 
9 rs2016394 2q31.1 DLX2 MALDI-TOF MS (Michailidou et al., 2013) 
10 rs16857609 2q35 DIRC3 MALDI-TOF MS (Michailidou et al., 2013) 
11 rs4442975 2q35 IGFBP5 MALDI-TOF MS (Ghoussaini et al., 2014) 
12 rs4973768 3p24.1 SLC4A7 MALDI-TOF MS (Ahmed et al., 2009) 
13 rs12493607 3p24.1 TGFBR2 MALDI-TOF MS (Michailidou et al., 2013) 
14 rs6762644 3p26.1 EGOT/ITPR1 MALDI-TOF MS (Michailidou et al., 2013) 
15 rs9790517 4q24 TET2 MALDI-TOF MS (Michailidou et al., 2013) 
16 rs6828523 4q34.1 ADAM29 MALDI-TOF MS (Michailidou et al., 2013) 
17 rs10941679 5p12 MRPS30 MALDI-TOF MS (Ghoussaini et al., 2016) 
18 rs10069690 5p15.33 TERT MALDI-TOF MS (Haiman et al., 2011) 
19 rs2736108 5p15.33 TERT TaqMan assay (Bojesen et al., 2013b) 
20 rs3215401 5p15.33 TERT MALDI-TOF MS (Bojesen et al., 2013b) 
21 rs2242652 5p15.33 TERT MALDI-TOF MS (Bojesen et al., 2013b) 
22 rs889312 5q11.2 MAP3K1 MALDI-TOF MS (Easton et al., 2007b) 
23 rs1353747 5q11.2 PDE4D MALDI-TOF MS (Michailidou et al., 2013) 
24 rs10472076 5q11.2 RAB3C MALDI-TOF MS (Michailidou et al., 2013) 
25 rs1432679 5q33.3 EBF1 MALDI-TOF MS (Michailidou et al., 2013) 
26 rs204247 6p23 RANBP9 MALDI-TOF MS (Michailidou et al., 2013) 
27 rs11242675 6p25.3 FOXQ1 MALDI-TOF MS (Michailidou et al., 2013) 
28 rs17530068 6q14.1 FAM46A MALDI-TOF MS (Siddiq et al., 2012) 
29 rs2046210 6q25.1 ESR1/CCDC170 MALDI-TOF MS (Zheng et al., 2009) 
30 rs720475 7q35 ARHGEF5/NOBOX MALDI-TOF MS (Michailidou et al., 2013) 
31 rs9693444 8p12 DUSP4 MALDI-TOF MS (Michailidou et al., 2013) 
32 rs6472903 8q21.11 HNF4G MALDI-TOF MS (Michailidou et al., 2013) 
33 rs13281615 8q24.21 POU5F1B MALDI-TOF MS (Easton et al., 2007b) 
34 rs11780156 8q24.21 PVT1/MYC MALDI-TOF MS (Michailidou et al., 2013) 
35 rs1011970 9p21.3 CDKN2A/B MALDI-TOF MS (Turnbull et al., 2010) 
36 rs10816625 9q31.2 KLF4 MALDI-TOF MS (Orr et al., 2015b) 
37 rs676256 9q31.2 KLF4 MALDI-TOF MS (Orr et al., 2015b) 
38 rs865686 9q31.2 KLF4 MALDI-TOF MS (Fletcher et al., 2011) 
39 rs10759243 9q31.2 KLF4 MALDI-TOF MS (Michailidou et al., 2013) 
40 rs11814448 10p12.31 DNAJC1 MALDI-TOF MS (Michailidou et al., 2013) 
41 rs7072776 10p12.31 MLLT10/DNAJC1 MALDI-TOF MS (Michailidou et al., 2013) 
42 rs10995190 10q21 ZNF365 MALDI-TOF MS (Turnbull et al., 2010) 
43 rs704010 10q22.3 ZMZ1 MALDI-TOF MS (Turnbull et al., 2010) 
44 rs7904519 10q25.2 TCF7L2 MALDI-TOF MS (Michailidou et al., 2013) 
45 rs11199914 10q26.12 FGFR2 MALDI-TOF MS (Michailidou et al., 2013) 
46 rs35054928 10q26.13 FGFR2 MALDI-TOF MS (Meyer et al., 2013) 
47 rs2981579 10q26.13 FGFR2 MALDI-TOF MS (Hunter et al., 2007a) 
48 rs2981578 10q26.13 FGFR2 MALDI-TOF MS (Meyer et al., 2013) 
49 rs3750817 10q26.13 FGFR2 MALDI-TOF MS (Easton et al., 2007b) 
50 rs11200014 10q26.13 FGFR2 MALDI-TOF MS (Hunter et al., 2007a) 
51 rs2420946 10q26.13 FGFR2 MALDI-TOF MS (Hunter et al., 2007a) 
52 rs3817198 11p15.5 LSP1 MALDI-TOF MS (Easton et al., 2007b) 
53 rs614367 11q13.3 MYEOV/CCND1 MALDI-TOF MS (Turnbull et al., 2010) 
54 rs3903072 11q13.1 CFL1/OVOL1 MALDI-TOF MS (Michailidou et al., 2013) 
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55 rs554219 11q13.3 CCND1 MALDI-TOF MS (French et al., 2013b) 
56 rs11820646 11q24.3 BARX2 MALDI-TOF MS (Michailidou et al., 2013) 
57 rs12422552 12p13.1 ATF7IP MALDI-TOF MS (Michailidou et al., 2013) 
58 rs17356907 12q22 NTN4 MALDI-TOF MS (Michailidou et al., 2013) 
59 rs1292011 12q24.21 MED13L/TBX3 MALDI-TOF MS (Ghoussaini et al., 2012) 
60 rs2236007 14q13.3 PAX9 MALDI-TOF MS (Michailidou et al., 2013) 
61 rs999737 14q24.1 RAD51B MALDI-TOF MS (Thomas et al., 2009) 
62 rs2588809 14q24.1 RAD51B MALDI-TOF MS (Michailidou et al., 2013) 
63 rs941764 14q32.11 CCDC88C MALDI-TOF MS (Michailidou et al., 2013) 
64 rs17817449 16q12.2 FTO MALDI-TOF MS (Michailidou et al., 2013) 
65 rs11075995 16q12.2 FTO MALDI-TOF MS (Garcia-Closas et al., 2013b) 
66 rs3803662 16q12.1 TOX3 MALDI-TOF MS (Stacey et al., 2007) 
67 rs4784227 16q12.1 TOX3 MALDI-TOF MS (Udler et al., 2010b) 
68 rs13329835 16q23.2 CDYL2 MALDI-TOF MS (Michailidou et al., 2013) 
69 rs6504950 17q22 STXBP4 MALDI-TOF MS (Ahmed et al., 2009) 
70 rs1436904 18q11.2 CHST9 MALDI-TOF MS (Michailidou et al., 2013) 
71 rs527616 18q11.2 AQP4 MALDI-TOF MS (Michailidou et al., 2013) 
72 rs8170 19p13.11 BABAM1=MERIT40 MALDI-TOF MS (Antoniou et al., 2010b) 
73 rs2363956 19p13.11 ANKLE1 MALDI-TOF MS (Antoniou et al., 2010b) 
74 rs4808801 19p13.11 ELL KASP assay (Michailidou et al., 2013) 
75 rs3760982 19q13.31 KCNN4/LYPD5 MALDI-TOF MS (Michailidou et al., 2013) 
76 rs2284378 20q11.22 RALY MALDI-TOF MS (Siddiq et al., 2012) 
77 rs2823093 21q21.1 NRIP1 MALDI-TOF MS (Ghoussaini et al., 2012) 
78 rs6001930 22q13.1 MKL1 MALDI-TOF MS (Michailidou et al., 2013) 
MALDI-TOF MS: matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. 
*Genome assembly GRCh37. 
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3.2.1. MALDI-TOF and TaqMan genotyping analyses 
Genomic DNA was extracted from 9 ml of peripheral blood collected in an EDTA tube 
using the salting out extraction method (Laitinen et al., 1994). Homogenous 
MassEXTEND and iPLEX GOLD methodology were carried out according to the 
manufacturer´s instructions (http://www.sequenom.com). Multiplex PCR assays were 
designed using the online tool Assay Design Suite 
(http://agenabio.com/products/massarraysystem/software/). In brief, 6.25 ng of 
genomic DNA was amplified by PCR in a final volume of 6.2 µl containing locus-
specific primers at 100 nM final concentrations and 0.5 units HotStarTaq DNA 
Polymerase (Qiagen, Hilden, Germany). PCR conditions were 94°C for 15 minutes 
for Hot start, followed by 45 cycles of denaturation at 94°C for 20 seconds, annealing 
at 56°C for 30 seconds, and extension for 1 minute at 72°C, finally followed by 
incubation at 72°C for 3 minutes. PCR products were treated with 0.6 units of shrimp 
alkaline phosphatase (SAP) enzyme (iPLEX Gold Reagent Kit, Sequenom) for 40 
minutes at 37°C to remove 5'- and 3'-phosphate groups from unincorporated dNTPs 
followed by 5 minutes at 85°C to inactivate SAP. After adjusting the concentrations of 
the extension primers according to their masses the base extension (homogenous 
MassEXTEND (hMETM), Sequenom) reactions were carried out in a final volume of 
10 µl containing 0.6 units polymerase (iPLEX enzyme, iPLEX Gold Reagent Kit, 
Sequenom). Base extension reaction conditions were 94°C for 30 seconds, followed 
by 40 cycles of 94°C for 5 seconds, 52°C for 5 seconds, and 80°C for 5 seconds. 
Within each of the 40 cycles the 52°C and 80°C steps were repeated 5 times. The 
final incubation was carried out at 72°C for 3 minutes. All reactions including PCR 
amplification, SAP treatment, and base extension were carried out in a DNA Engine 
DYAD PTC 220 PCR thermal cycler (MJ Research, USA). For a final volume of 26 µl, 
16 µl of DNase/RNase free water (Life Technologies, USA) was added to each base 
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extension reaction. The final base extension products were treated with 
SpectroCLEAN resin (Sequenom) to remove salts from the reaction buffer. Following 
a quick centrifugation (2,000 rpm, 3 minutes in an Eppendorf Centrifuge 5810, 
Hamburg, Germany), 10 nl of reaction solution was dispensed onto a 384 format 
SpectroCHIP microarray (Sequenom) prespotted with a matrix of 3-hydroxypicolinic 
acid (3-HPA) by using a SpectroPointnanodispenser (Sequenom). A modified Bruker 
Biflex MALDI-TOF MS was used for data acquisitions from the SpectroCHIP. 
Genotype calls were made in real time with MassARRAY RT software vers. 3.0.0.4 
(Sequenom). Post run cluster analysis was performed with MassARRAYTyper 
vers.4.0 (Sequenom). All primers were synthesized by Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany. Primer sequences are shown in Supporting Information, Table 
S1. 
Figure 5 shows exemplary genotype cluster plots and MALDI-TOF MS spectra 
representing homozygous and heterozygous genotypes for rs2981578 (FGFR2), 
rs941764 (CCDC88C), rs4784227 (TOX3), and rs2823093 (NRIP1).  
For genotyping by TaqMan allelic discrimination analysis, 6.25 ng of genomic DNA 
was amplified in a final volume of 5 µl containing DNase/RNase free water, TaqMan® 
Genotyping Master Mix (Applied Biosystems, USA), and 20x SNP Genotyping Assay 
according to the manufacturer’s instructions. PCR conditions were 95°C for 10 
minutes for hot start, followed by 60 cycles of denaturation at 95°C for 15 seconds, 
annealing at 60°C for 1 minute, and a final cooling step at 40°C for 30 seconds. Real 
time PCR was performed with the LightCycler 480 Real-Time PCR System (Roche 
Diagnostics International AG, Switzerland) using its Endpoint Genotyping application 
module.  




Figure 5: MALDI-TOF MS genotyping analysis. Exemplary genotype cluster plots (left panels) and MS 
spectra (right panels) for rs2981578 (A>G in FGFR2) (A), rs941764 (A>G in CCDC88C) (B), 
rs4784227 (C>T in TOX3) (C), and rs2823093 (G>A in NRIP1) (D). Green squares represent 
heterozygous genotypes, yellow and blue triangles represent homozygous genotypes, and red circles 
represent negative controls and drop outs. Masses of the expected unextended primers are marked 
by the red dotted line and both extension products (allele 1 and allele 2) by the blue dotted lines. 
Masses are given in Dalton.  
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3.3. Statistical analyses 
3.3.1. Imputation of missing ancestry informative markers 
Genotype imputation is the process of estimating and replacing missing values in 
untyped genotypes in genetic studies (Li et al., 2009). Standard genotype imputation 
methods, like IMPUTE2, rely on linkage disequilibrium patterns and are not 
appropriate for a set of unlinked variants. Therefore, alternative statistical techniques 
for multiple imputations were applied.  
3.3.1.1. Mechanism, patterns and types of variables for missing data 
The generated missing values follow a process that is described by the missing data 
mechanism. Three types of missingness mechanisms are described in the literature 
(He, 2010):  
 Missing completely at random (MCAR): The probability a variable is missing 
does not depend on any other observed variables. The missing values have 
no systematic differences with the observed values. 
 Missing at random (MAR): The probability of missingness depends only on 
observed variables. In other words, the missingness on a given variable can 
be predicted using other variables in the dataset. 
 Missing not at random (MNAR): The value of the unobserved variable itself 
predicts missingness.  
A correct assumption about the missing data mechanism is essential for accurate 
statistical inferences. MAR mechanism cannot be tested considering the observed 
data alone and MNAR assumption claim something that is not accessible from the 
observed data. However, it is possible to check if the data follow an MCAR 
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mechanism, comparing if the dataset with and without missing data didn’t have 
significant differences (He, 2010). 
 
Figure 6: Patterns of missing data. 
The missing data patterns can be classified in monotone or not. A dataset has a 
monotone missing pattern when Vj is missing then all the subsequent variables Vk, 
k>j are also missing (Figure 6) (Dong and Peng, 2013).  
Another important consideration in the quality of an imputation is the proportion of 
missing data. Schafer considered that a missing rate less or equal than 5% is 
irrelevant (Schafer, 1999). On the other hand, if more than 10% of data are missing, 
there is a risk of biased statistical analysis (Bennett, 2001).  
The type of variables (numeric or character) that either will contribute to the 
imputation process or is required for the imputation method should be taken into 
account in planning an imputation. Special consideration to the variable type will help 
ensure that the imputation is well conducted (Hayati Rezvan et al., 2015). 
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3.3.1.2. Multiple imputation 
The multiple imputation approach assumes MAR condition, creates multiple 
completed datasets, generating possible replacements for each missing value (He, 
2010) (Figure 7).  
There is not a consensus of how many imputations should be done. Schafer (1999) 
stated that “unless rates of missing information are unusually high, there tends to be 
little or no practical benefit to using more than five to ten imputations” (Schafer, 
1999). Bodner (2008) recommends having as many imputations as the percentage of 
missing data (Bodner, 2008). One parameter used to select the number of 
imputations is the relative efficiency (Pan et al., 2014): 






where m is the number of imputations and λ the proportion of missing data. The 
number of imputations is directly proportional to the amount of missing information. 
Once the complete datasets are generated, the second step is to fit statistical 
methods to each imputed dataset. Estimations in each of the imputed datasets will 
differ because of the variation present in the multiple imputations. The next step is to 
average the estimations in order to obtain an overall result (Sterne et al., 2009). 
  




Figure 7: Steps in multiple imputation. The process starts with an incomplete dataset (on the left 
side), which is imputed n times (n=3) thus creating n completed datasets. Each complete dataset is 
analyzed, resulting in n analysis results. Finally, these n results are pooled into one final result 
(Adapted from https://www.slideshare.net/otrec/kim-slides-01232015). 
3.3.1.3. The MI procedure in SAS 
The SAS PROC MI package includes multiple imputation procedures, depending on 
the pattern of missingness and the type of the imputed variables, as summarized in 
Table 3 (Inc, 2012). 
There are three methods available for datasets with monotone missing patterns and 
continuous variables: a regression method, a predictive mean-matching method, or a 
propensity score method. 
The logistic regression method or the discriminant function method can be used to 
impute missing values in datasets with classification variables and monotone missing 
patterns. 
Markov chain Monte Carlo (MCMC) methods assume multivariate normality and can 
be applied in datasets with arbitrary missing patterns and continuous variables. 
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Table 3: Imputation methods in SAS Procedure MI 
Pattern of 
missingness 





Monotone Continuous Arbitrary Monotone regression 
Monotone predicted mean matching 
Monotone propensity score 
Monotone Classification (ordinal) Arbitrary Monotone logistic regression 
Monotone Classification (nominal) Arbitrary Monotone discriminant function 
Arbitrary Continuous Continuous MCMC full-data imputation 
MCMC monotone-data imputation 
Arbitrary Continuous Arbitrary FCS regression 
 FCS predicted mean matching 
Arbitrary Classification (ordinal) Arbitrary FCS logistic regression 
Arbitrary Classification (nominal) Arbitrary FCS discriminant function 
*Adapted from Table 56.5 Imputation Methods in PROC MI. SAS Procedures Guide. Version 9.3, 
Cary, NC: SAS Institute Inc. 
FCS methods can be effectively applied to impute missing values for continuous and 
classification variables in datasets with arbitrary missing patterns. 
3.3.1.4. Missing data problem in this study 
Of the 2,045 study participants (1,022 cases and 1,023 controls), 1,344 (722 cases 
and 622 controls) had complete data available for all 30 AIMs. Complete non-missing 
data on all 30 AIMs is required in order to estimate the proportion of genetic ancestry. 
For this reason, missing marker genotypes were imputed for participants with at least 
27 non-missing AIMs (1,842 samples, 989 cases and 853 controls). Table 4 shows 
the name of each AIM, the number, and percent of missing data. The data show 
moderate missing values for each AIM. 
A multiple imputation analysis was carried out using the PROC MI procedure in SAS. 
A discriminant function method was chosen and data were imputed using seven 
iterations to achieve relative efficiencies of 99%.  
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Table 4: Missing values and percentages for each AIM 
 
Missing values 
AIM N % 
rs10037656 16 0.87 
rs10510511 10 0.54 
rs10935320 18 0.98 
rs11725412 12 0.65 
rs1197062 13 0.71 
rs12347078 20 1.09 
rs1243370 140 7.60 
rs12662498 26 1.41 
rs1544450 5 0.27 
rs1559163 20 1.09 
rs17086231 8 0.43 
rs174570 16 0.87 
rs1834619 32 1.74 
rs1849384 14 0.76 
rs2042314 73 3.96 
rs2052386 3 0.16 
rs2176046 19 1.03 
rs2426552 6 0.33 
rs260690 11 0.60 
rs2719921 11 0.60 
rs356652 6 0.33 
rs3870336 63 3.42 
rs4145160 51 2.77 
rs4769128 27 1.47 
rs6119879 14 0.76 
rs6464749 4 0.22 
rs7018273 5 0.27 
rs7134749 39 2.12 
rs717225 10 0.54 
rs734241 12 0.65 
3.3.2. Estimation of ancestry proportions 
Genetic ancestry estimation has been applied in genetic association studies to 
analyze population stratification. It explains the genetic basis for ethnic differences in 
disease susceptibility (Liu et al., 2013).  
Computer programs like STRUCTURE and ADMIXTURE are extensively used for 
estimating global genetic ancestry. STRUCTURE is based on a clustering approach 
which utilizes multi-locus genotype data to infer admixture proportions. It assigns 
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individuals to populations and estimates ancestral population allele frequencies in 
admixed populations (Pritchard et al., 2000). The ADMIXTURE software uses the 
same statistical model as STRUCTURE with faster estimation time (Alexander et al., 
2009). 
In this thesis, the ADMIXTURE program was used for supervised estimation of 
individual European, African, and Native American ancestry proportions. Reference 
individuals rely on 80 Utah residents with Northern and Western European ancestry 
and 87 Yorubas in Ibadan, Nigeria from the 1000 Genome Project as surrogates of 
European and African ancestry, respectively, and on 64 samples from the Americas 
in the Human Genome Diversity Project as Native American (Alexander et al., 2009; 
Cavalli-Sforza, 2005; Genomes Project et al., 2015; Price et al., 2006). 
3.3.3. Genetic principal component analysis for adjustment of population 
stratification 
The EIGENSTRAT method for genetic principal component analysis (PCA) was 
conducted to reduce the high-dimensionality of genetic data and to stratify the set of 
individuals into genetically similar groups (Price et al., 2006).  
The method consists of three steps. Suppose there are 𝑁 individuals genotyped at 𝑀 
SNPs. First, EIGENSTRAT centered and normalized the genotypes for each sample 
(Price et al., 2006). For each individual 𝑖, let 𝑋𝑖𝑗 be the resulting genotype data at 
SNP 𝑗, and let 𝑌𝑖 be the phenotype information. The empirical covariance matrix Ψ 
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where 𝑝𝑠 is an allele frequency estimate at marker 𝑠. Intuitively, the top eigenvectors 
of a covariance matrix between samples describe the variability of the axes. Then, 
EIGENSTRAT adjusts for genotypes and phenotypes using the top principal 
components obtained from Ψ as covariates in a multi-linear regression 
𝑌𝑖 = 𝛼 + 𝛽1𝑣𝑖1 + 𝛽2𝑣𝑖2 + ⋯ + 𝛽𝐾𝑣𝑖𝐾 + 𝛾𝑋𝑖𝑠 + 𝜖𝑖 
Here, 𝑣𝑖𝐾 is the ancestry of individual 𝑖 along the 𝑘
th axis of variation, which equals 
the 𝑖th coordinate of the 𝑘th eigenvector, and 𝐾 is the number of axes of variation 
used to adjust for ancestry.  
After ancestry adjustment, the method computes association statistics using 
ancestry-adjusted genotypes and phenotypes which a generalization of the Armitage 
trend 𝜒2 statistic. The objective is to test for correlations between two projected 
vectors into a space of reduced dimension. The test statistic is defined as  
𝐸𝐺 = (𝑁 − 𝐾 − 1)𝐶𝑜𝑟𝑟2(𝑋𝑠
𝑎𝑑𝑗 , 𝑌𝑎𝑑𝑗) 
where 𝑋𝑠
𝑎𝑑𝑗
 is the adjusted genotype at marker 𝑠, defined as the residuals after 
regressing genotypes on the top 𝐾 principal component. The adjusted 𝑌𝑎𝑑𝑗  is 
similarly defined (Price et al., 2006; Wu et al., 2011). The top principal components 
reflect the major ancestral dimensions of the study. 
3.3.4. Association and interaction analyses for common breast cancer 
susceptibility variants 
Possible interactions with genetic ancestry and associations with newly identified 
common BC susceptibility variants were tested using logistic regression with BC as 
response variable. For individual genotypes an additive model was assumed. 
Separate statistical analyses were performed for any type of BC, ER+, and ER- BC. 
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3.3.5. Variance in liability explained by identified susceptibility variants 
The heritability or variance in BC liability explained by associated risk variants was 
calculated based on a multifactorial liability threshold model (So et al., 2011). This 
model proposes a latent continuous liability, which is assumed to follow a normal 
distribution with mean 0 and variance 1. The mean liability is assumed to differ 
between genotypes, denoting risk allele 𝐴 and protective allele 𝑎. Calculations relied 
on the frequency of the high risk allele (𝑃𝐴), the relative risks for homozygote (𝑅𝑅1) 
and heterozygote genotypes (𝑅𝑅2), and the cumulative BC risk by age 80 years (𝐾) 
in Colombian (0.052) and European (0.087) women (Boyle and Ferlay, 2005; 
Hemminki and Bermejo, 2007). 
The genotype frequencies of the three genotypes 𝑃𝑎𝑎 , 𝑃 𝐴𝑎 , and 𝑃𝐴𝐴 were calculated 
assuming Hardy-Weinberg disequilibrium. The penetrance for each genotype was 
calculated based on the relative risk and the overall probability of disease in the 
population, which is given by 
𝑓𝑎𝑎 =
𝐾
(𝑃𝑎𝑎 + 𝑃𝐴𝑎 ∗ 𝑅𝑅1 + 𝑃𝐴𝐴 ∗ 𝑅𝑅2)
 
𝑓𝐴𝑎 = 𝑅𝑅1 ∗ 𝑓𝑎𝑎 
𝑓𝐴𝑎 = 𝑅𝑅2 ∗ 𝑓𝑎𝑎 
Assuming that the residual variance of each genotype is 1, the genotype-specific 
mean liabilities and the overall mean liability are given by  
𝜇𝑎𝑎 = 𝑇 − 𝜙
−1(1 − 𝑓𝑎𝑎) 
𝜇𝐴𝑎 = 𝑇 − 𝜙
−1(1 − 𝑓𝐴𝑎) 
𝜇𝐴𝐴 = 𝑇 − 𝜙
−1(1 − 𝑓𝐴𝐴) 
𝜇𝑎𝑙𝑙 = 𝑃𝐴𝑎 ∗ 𝜇𝐴𝑎 + 𝑃𝐴𝐴 ∗ 𝜇𝐴𝐴 
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where  𝑇 is the liability threshold and 𝜙−1 represents the quantile of the normal 
distribution. 
The three genotypic classes have the same residual variance with different mean 
liabilities. The variance explained by the locus can be written as: 
𝑉∗ = 𝑃𝐴
2(𝜇𝐴𝐴 − 𝜇𝑎𝑙𝑙)




To allow for comparisons with heritability estimates, a standardized variance in 





A scatter plot was used to compare the contribution of each risk variant to BC 
heritability in Colombian and European women. 
3.3.6. Area under the Receiver Operating Characteristic curve 
Logistic regression models were also fitted to study data to estimate the area under 
Receiver Operating Characteristic curve (AUC) as measure of discrimination ability 
for the established risk factors age, family history of BC in first-degree female 
relatives, oral contraceptive use, menopausal status and hormone therapy, BMI, 
current smoking, parity, age at first full-term pregnancy, age at menarche, and 
breastfeeding, alone and in combination with common variants associated with BC 
risk in Colombia and individual ancestry proportions. 
3.3.7. Development of the multifactorial risk score 
In order to further investigate the association between BC risk and the combined 
effects of established BC risk factors, common variants associated with BC risk in 
Colombia, and individual ancestry proportions, a MRS was built using the formula: 
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𝑀𝑅𝑆 = 𝛽1𝑥1 + 𝛽2𝑥2 + ⋯ + 𝛽𝑘𝑥𝑘 + ⋯ + 𝛽𝑛𝑥𝑛               (1) 
where 𝛽𝑘 represents the estimated log ORs from a multiple logistic regression model. 
The model included the ten risk factors listed in Table 1, the estimated individual 
Native American proportions, and variants associated with risk in Colombia assuming 
an additive model taking into account risk estimates from the literature and from 






In this work, genetic polymorphisms and ancestry have been investigated for their 
role in BC risk in Colombian women. The results of the project are divided into six 
parts as listed below: 
 Description of the study participants: baseline characteristics, geographical 
distribution, genetic ancestry, and BC incidence 
 
 Associations between 78 recently identified common risk variants and BC risk 
in Colombian women 
 
 Risk associations between 78 recently identified common risk variants and ER 
status in Colombian women 
 
 Variance in BC liability for 78 common variants in Europe and Colombia  
 
 Interactions between common variants and genetic ancestry on BC 
susceptibility  
 
 Discrimination ability of established risk factors, genetic ancestry, and 





4.1. Description of the study participants: baseline characteristics, 
geographical distribution, genetic ancestry, and breast cancer 
incidence 
The Col-BCCC study population included 1,022 BC patients unselected for family 
history and age at BC diagnosis, and 1,023 healthy controls for which detailed 
information and DNA samples were available. Their baseline characteristics are 
given in Table 1. Age, BMI, and age at menarche showed similar distributions in 
cases and controls. Different distributions were noticed for smoking status, parity, 
age at first full-term pregnancy, and breastfeeding. Study individuals affected by BC 
had larger proportions of family history of BC in first-degree female relatives and oral 
contraceptive use than non-affected controls. The use of hormone therapy was 
higher in postmenopausal women affected by BC than in non-affected controls.  
Figure 8 shows the BC incidence rates in Colombia, geographical distribution of the 
study participants, results from a genetic PCA, and the estimated ancestry 
proportions. Panel 8A shows the regional BC incidence in Colombia using previously 
published data from the National Cancer Institute of Colombia corresponding to the 
period 2007-2011 (Pardo and Cendales, 2009) 
(http://www.cancer.gov.co/files/libros/archivos/incidencia1.pdf; Table 83). The 
geographical distribution of study participants is shown in Panel 8B (BC cases) and 
Panel 8C (controls). The majority of study women were recruited in the central part of 
Colombia (Cundinamarca and Huila regions). Panel 8D shows results from a genetic 
PCA of study individuals. The first principal component separated non-African from 
African ancestry components and explained 24.1% of genetic variability. The second 
principal component separated the Native American and European ancestry 




women have the highest average with an amount of 55.3% (5th-95th percentiles: 
28.2%-80.7%). Followed by the average of Native American proportions 37.8% (5th-
95th percentiles: 11.7%-63.0%) and the average of African proportions was 5.3% (5th-
95th percentiles: 0.0%-22.5%).  
 
Figure 8: Breast cancer incidence rates in Colombia and description of the study participants. (A) 
Regional breast cancer incidence in Colombia. (B) Geographical distribution of the study cases. (C) 
Geographical distribution of the study controls. (D) First two principal components reflecting genetic 
variation among the study participants and three populations from the 1000 Genomes Project (Utah 
residents with Northern and Western European ancestry from the CEPH collection; Yoruba in Ibadan, 
Nigeria and the Human Genome Diversity Project (samples from the Americas). (E-G) Regional 
estimates of Native American, European, and African ancestry proportions. 
Native American ancestry proportions were lower in Colombian BC patients than 
unaffected controls (P-value=5.2x10-16). Per each 1% increase in the Native 
American proportion the unadjusted risk of BC decreased by 2.6% (95% CI: 2.0-3.2). 
After adjustment for established risk factors, the risk reduction was 2.2% (95% CI: 
1.4-2.9). Contrarily, per each 1% increase in the European proportion the adjusted 
risk of BC increased by 1.6% (95% CI: 0.9-2.3).The association between BC risk and 
African ancestry proportions did not reach statistical significance (unadjusted P-
value=0.32, adjusted P-value=0.08). Panels 8E-G show regional estimates of 




individuals, confirming the inverse association between increasing Native American 
proportions and decreasing BC risk (Figure 8a, e). 
4.2. Associations between 78 recently identified common risk variants and 
breast cancer risk in Colombian women 
Out of 78 common variants robustly associated with BC risk in women of European 
origin, 13 showed nominal associations with BC risk in Colombia. Two variants 
rs3803662 (TOX3) and rs11199914 (FGFR2) revealed probability values smaller 
than 0.05 after potential cofounder and multiplicity adjustment using multiple 
permutation (Table 5). Complete results for all 78 investigated variants are presented 
in Supporting Information, Table S2. As expected, the allele frequencies of 
associated variants were partially different in Europeans and Colombians. For 
example, the major G allele for SNP rs4442975 (gene/nearest gene IGFBP5) among 
Europeans was the less frequent allele in Colombians, with a minor allele frequency 
equal to 0.35 (95% CI: 0.32-0.38, non-overlapping CIs). In general, adjustment for 
potential confounders barely affected the estimated ORs. Risk effects estimated for 
associated variants were also partially different in Europeans and Colombians. 
Estimated allele frequencies and risk effects for women of Asian and Colombian 




Table 5: Common variants associated with breast cancer susceptibility in European and Colombian women 
Abbreviations: MAF, minor allele frequency; AF, allele frequency; OR, odds ratio; adj., adjusted; CI, confidence interval. 
*Genome assembly GRCh37. 
1AFs and ORs different in Europe and Colombia (non-overlapping confidence intervals) are marked in bold. 
2P-values smaller than 0.05 are marked in bold, P-values smaller than 0.05 after multiplicity correction using multiple permutation are underlined. 
3OR adjusted for age, family history of breast cancer in first-degree female relatives, oral contraceptive use, menopausal status combined with postmenopausal 
hormone therapy use, body mass index, smoking status, parity, age at first full-term pregnancy, age at menarche, and breastfeeding. 
SNP ID Locus 
Gene/nearest 
gene(s)* 
EUROPEANS COLOMBIANS Ref.  
Alleles 
Major/Minor MAF OR AF1 95% CI OR1 95% CI P-value2 ORadj.3 95% CI P-value2 
 
rs4442975 2q35 IGFBP5 G/T 0.49 0.87 0.65 0.62 0.68 0.82 0.65 0.96 0.01 0.82 0.62 0.99 0.03 
(Ghoussaini et 
al., 2014) 
rs2046210 6q25.1 ESR1/CCDC170 G/A 0.34 1.08 0.26 0.24 0.29 1.18 1.03 1.36 0.02 1.30 1.11 1.54 0.002 
(Michailidou et 
al., 2013) 
rs10759243 9q31.2 KLF4 C/A 0.39 1.06 0.43 0.40 0.46 1.15 1.01 1.30 0.03 1.18 1.01 1.37 0.03 
(Michailidou et 
al., 2013) 
rs11199914 10q26.12 FGFR2 C/T 0.32 0.95 0.43 0.40 0.46 0.79 0.69 0.89 0.0002 0.77 0.66 0.89 0.0007 
(Michailidou et 
al., 2013) 
rs35054928 10q26.13 FGFR2 -/C 0.44 1.27 0.39 0.36 0.42 1.20 1.06 1.36 0.005 1.17 1.00 1.35 0.05 
(Meyer et al., 
2013) 
rs2981579 10q26.13 FGFR2  G/A 0.40 1.27 0.39 0.36 0.42 1.21 1.06 1.37 0.003 1.17 1.00 1.35 0.05 
(Michailidou et 
al., 2013) 
rs2981578 10q26.13 FGFR2 T/C 0.49 1.24 0.46 0.43 0.49 1.24 1.10 1.41 0.0005 1.20 1.03 1.38 0.02 
(Meyer et al., 
2013) 
rs2588809 14q24.1 RAD51B  C/T 0.16 1.08 0.16 0.14 0.18 1.28 1.09 1.51 0.003 1.31 1.07 1.59 0.008 
(Michailidou et 
al., 2013) 
rs941764 14q32.11 CCDC88C A/G 0.34 1.06 0.42 0.39 0.45 1.21 1.06 1.37 0.004 1.26 1.08 1.46 0.003 
(Michailidou et 
al., 2013) 
rs3803662 16q12.1 TOX3 G/A 0.26 1.24 0.43 0.40 0.46 1.21 1.07 1.37 0.003 1.30 1.12 1.51 0.0007 
(Michailidou et 
al., 2013) 
rs4784227 16q12.1 TOX3 C/T 0.25 1.19 0.35 0.32 0.38 1.21 1.07 1.38 0.003 1.20 1.03 1.40 0.02 
(Long et al., 
2010) 
rs13329835 16q23.2 CDYL2  A/G 0.22 1.08 0.17 0.15 0.20 1.22 1.04 1.43 0.02 1.23 1.02 1.49 0.03 
(Michailidou et 
al., 2013) 






4.3. Risk associations by estrogen receptor status 
Risk associations by ER status of diagnosed breast tumors are shown in Table 6. 
One variant was specifically associated with ER+ disease and three variants with ER- 
disease in Colombian women. Out of 13 variants associated with BC risk in 
Colombia, three variants did not show an association with either ER+ or ER- disease, 
one variant was associated with ER- , seven with ER+, and three with ER+ and ER- 
BC. 
However, the estimated risk differences for ER+ and ER- disease did not reach 
statistical significance. For example, SNP rs2823093 (NRIP1) showed an OR of 0.73 
(95% CI: 0.60-0.89) for ER+ BC, compared to an OR of 0.94 (95% CI: 0.70-1.26) for 
ER- BC (overlapping CIs). Risk associations by ER status for all 78 investigated 
variants are presented in Supporting Information, Table S4. 
4.4. Variance in breast cancer liability 
Estimated risk allele frequencies were combined with genotype relative risks to 
assess the variance in BC liability due to susceptibility variants in European and 
Colombian women. Results are represented in Figure 9. Four out of 13 variants 
associated with BC risk in Colombia explained a larger proportion of heritability in 
Europe than in Colombia, with SNP rs35054928 (FGR2) explaining the largest 
variance proportion in Europe (0.0071) as previously reported. By contrast, nine 
associated variants showed a larger attributable heritability in Colombia than in 






Table 6: Associations with breast cancer susceptibility by estrogen receptor status 
SNP ID Locus 
Gene/nearest 
gene(s)*  
ER-positive (N=592) ER-negative (N=170) Associated 
breast cancer 
type 
ORadj.1 95% CI P-value2 ORadj.
1 
95% CI P-value2 
rs889312 5q11.2 MAP3K1 1.25 1.05 1.49 0.01 0.85 0.65 1.11 0.24 ER+ 
rs6762644 3p26.1 EGOT/ITPR1 1.03 0.86 1.24 0.75 1.48 1.12 1.94 0.005 ER- 
rs1011970 9p21.3 CDKN2A/B 1.00 0.84 1.19 0.99 1.38 1.07 1.79 0.01 ER- 
rs6504950 17q22 STXBP4 0.99 0.80 1.23 0.95 1.46 1.08 1.98 0.01 ER- 
rs2981579 10q26.13 FGFR2  1.16 0.97 1.38 0.10 1.33 1.02 1.74 0.04 overall, ER- 
rs35054928 10q26.13 FGFR2 1.20 1.01 1.43 0.04 1.23 0.94 1.61 0.13 overall, ER+ 
rs2981578 10q26.13 FGFR2 1.24 1.05 1.48 0.01 1.27 0.98 1.65 0.07 overall, ER+ 
rs2588809 14q24.1 RAD51B  1.28 1.01 1.61 0.04 1.16 0.81 1.64 0.40 overall, ER+ 
rs3803662 16q12.1 TOX3 1.33 1.12 1.58 0.001 1.06 0.80 1.38 0.70 overall, ER+ 
rs4784227 16q12.1 TOX3 1.25 1.05 1.49 0.01 1.06 0.81 1.40 0.67 overall, ER+ 
rs2823093 21q21.1 NRIP1  0.73 0.60 0.89 0.002 0.94 0.70 1.26 0.69 overall, ER+ 
rs2046210 6q25.1 ESR1/CCDC170 1.33 1.10 1.61 0.003 1.34 1.00 1.78 0.05 overall, ER+, ER- 
rs11199914 10q26.12 FGFR2 0.74 0.62 0.89 0.001 0.75 0.57 0.99 0.04 overall, ER+, ER- 
rs941764 14q32.11 CCDC88C 1.30 1.09 1.55 0.004 1.42 1.08 1.86 0.01 overall, ER+, ER- 
Abbreviations: ER+, estrogen receptor positive; ER-, estrogen receptor negative; OR, odds ratio; adj., adjusted; CI, confidence interval. 
*Genome assembly GRCh37. 
1OR adjusted for age, family history of breast cancer in first-degree female relatives, oral contraceptive use, menopausal status combined with  
 postmenopausal hormone therapy use, body mass index, smoking status, parity, age at first full-term pregnancy, age at menarche, and breastfeeding. 





Figure 9: Fractions of explained variance for the 78 investigated common variants in Europe and 
Colombia. Black dots indicate the 13 variants with associated P-values smaller than 0.05; grey dots 
indicate the 65 variants with P-values higher than 0.05 in Colombia. 
4.5. Interactions between common variants and genetic ancestry on breast 
cancer susceptibility 
Results from logistic regression analyses revealed statistically significant interactions 
between two common BC susceptibility variants and genetic ancestry. Table 7 shows 
detailed results on the identified interactions with European proportions. When study 
women were grouped into four categories according to the quartiles of European 
proportions (1st quartile 45%, 2nd quartile 55%, 3rd quartile 66%), the strength of the 




European proportions from OR=1.32 for equal or less than 45% European ancestry 
to OR=1.07 for over 66% European ancestry. The opposite moderation of genetic 
risk by European ancestry was noticed for SNP rs941764 (CCDC88C). The OR 
increased from 0.91 for equal or less than 45% European ancestry to 1.76 for over 
66% European ancestry. Interactions between the 13 risk SNPs and European and 
Native American proportions are shown in Supporting Information, Tables S5 and S6, 
respectively.  
4.6. Discrimination ability of established risk factors, genetic ancestry and 
common breast cancer susceptibility variants, and estimated breast 
cancer risks based on a multifactorial risk score 
The ability of established BC risk factors, Native American proportions, and variants 
associated with BC risk in Colombia to separate affected cases from unaffected 
healthy controls was investigated. The central part of Table 8 shows estimates based 
on own genotype and risk factor data combined with information from the literature 
on European genetic risk estimates and risk estimates for established BC risk factors 
in Hispanic women. The AUCs on the right of the table were based on own 
Colombian data only. Native American ancestry proportions resulted in the highest 
AUC (0.61), followed by the established risk factors “family history of BC in first-
degree female relatives” (AUC=0.58), and “breastfeeding” (AUC=0.55). With the 
exception of the risk factor “parity”, AUC estimates based on the literature and on the 
own Colombian data were similar.  
The combination of all 13 variants associated with BC risk in Colombia resulted in an 
AUC of 0.57, similar to the discrimination ability of Native American proportions. The 
true discrimination ability of the combined established risk factors, Native American 




the rather conservative AUCs that integrate European and Hispanic risk estimates 
from the literature (AUC=0.65, 95% CI: 0.62-0.68) and the over-optimistic results 








Group of women according to the quartiles of European ancestry 
(ancestry range, N cases, N controls) 
SNP ID Locus 
Gene/nearest 
gene(s)*  
Interaction 0-45.0%, 218, 243 45.1%-55.0%, 225, 235 55.1%-66.0%, 231, 229 66.1%-100%, 315, 146 
P-value1 ORadj.2 95% CI ORadj.2 95% CI ORadj.2 95% CI ORadj.2 95% CI 
rs941764 14q32.11 CCDC88C 0.02 0.91 0.65 1.27 1.29 0.94 1.78 1.63 1.18 2.27 1.76 1.23 2.56 
rs3803662 16q12.1 TOX3 0.03 1.32 0.96 1.84 1.46 1.06 2.04 1.35 0.99 1.85 1.07 0.74 1.56 
Abbreviations: OR, odds ratio; adj., adjusted; CI, confidence interval. 
*Genome assembly GRCh37. 
1P-values smaller than 0.05 are marked in bold. 
2OR adjusted for age, family history of breast cancer in first-degree female relatives, oral contraceptive use, menopausal status combined with postmenopausal 




Table 8: Estimated AUCs with their corresponding 95% confidence intervals (CIs) for established risk factors, genetic ancestry, and common breast cancer 
susceptibility variants based on risk estimates from the literature and own Colombian data 
Risk factor 
 
Based on risk estimates from literature 
Exclusively based on own 
Colombian data 
Established risk factors  OR 95% CI Ref. AUC 95% CI OR 95% CI AUC 95% CI 
Age (years)  1.043 1.041 1.046 (Ferlay et al., 2015) 0.53 0.51 0.56 1.01 1.00 1.02 0.53 0.51 0.56 
Family history of breast 
cancer in first-degree 
female relatives 
No Ref.  (Banegas et al., 2017)    Ref.      
Yes 
2.48 1.67 3.68  0.58 0.56 0.60 3.04 2.30 4.07 0.58 0.56 0.60 
Oral contraceptive use  
No Ref.  (Hines et al., 2010)     Ref.     
Yes 1.36 0.96 1.92  0.53 0.51 0.55 1.19 0.96 1.47 0.53 0.51 0.55 
Menopausal status and  
hormone therapy use 
 
Premenopausal and 
postmenopausal who never 
used hormone therapy 
Ref. 
  
(Amadou et al., 2013) 
    
Ref. 
      
Postmenopausal women who 
ever used hormone therapy 1.78 1.32 2.41  0.54 0.52 0.55 2.11 1.41 3.20 0.54 0.52 0.55 
Body mass index  (kg/m2) 
<25   1.23 0.81 1.87     1.19 0.87 1.63    
25-29.9  1.10 0.72 1.67 (Hines et al., 2010) 0.53 0.51 0.56 1.00 0.73 1.37 0.53 0.51 0.55 
≥30   Ref.      Ref.      
Smoking status 
Never Ref.      Ref.      
Former 1.43 1.04 1.96 (Connor et al., 2016) 0.53 0.51 0.55 1.36 1.08 1.73 0.54 0.52 0.56 
Current 0.82 0.62 1.08     1.14 0.76 1.74    
Parity  Nulliparous 0.95 0.50 1.83     1.13 0.64 1.97    
 1-2 0.96 0.64 1.44 (Hines et al., 2010) 0.46 0.44 0.49 1.29 1.02 1.64 0.53 0.51 0.56 
 >3 Ref.     Ref.      
Age at first full-term 
pregnancy (years) 
<20 Ref.      Ref.      
20-29 1.60 1.35 1.88 (Banegas et al., 2017) 0.54 0.51 0.56 0.93 0.72 1.21 0.53 0.50 0.55 
>30 2.54 1.84 3.53     1.59 1.13 2.26    
Age at menarche (years) 
>14 Ref.      Ref.      
12-13 1.30 1.12 1.50 (Banegas et al., 2017) 0.51 0.49 0.54 1.12 0.90 1.38 0.52 0.49 0.54 
<12 1.68 1.26 2.25     1.07 0.80 1.44    
Breastfeeding (months) Never 1.40 0.87 2.27     1.58 0.99 2.54    
 <12 1.09 0.70 1.69 (Hines et al., 2010) 0.55 0.52 0.57 1.10 0.86 1.40 0.55 0.52 0.57 
 >12 Ref.      Ref.      
Established risk factors 
combined 
 








0.31 0.18 0.54 (Fejerman et al., 2014) 0.61 0.58 0.63 0.07 0.04 0.13 0.61 0.58 0.63 
Established risk factors 
and genetic ancestry 
combined 
 




             
rs4442975  0.87 0.86 0.89 (Ghoussaini et al., 2014) 0.46 0.44 0.49 0.82 0.62 0.99 0.46 0.44 0.49 
rs2046210  1.08 1.06 1.10 (Michailidou et al., 2013) 0.52 0.50 0.54 1.30 1.11 1.54 0.52 0.50 0.54 
rs10759243  1.06 1.04 1.08 (Michailidou et al., 2013) 0.53 0.51 0.55 1.18 1.01 1.37 0.53 0.51 0.55 
rs11199914  0.95 0.93 0.97 (Michailidou et al., 2013) 0.54 0.52 0.56 0.77 0.66 0.89 0.54 0.52 0.56 
rs35054928  1.27 1.24 1.29 (Meyer et al., 2013) 0.53 0.51 0.56 1.17 1.00 1.35 0.53 0.51 0.56 
rs2981579  1.27 1.24 1.29 (Michailidou et al., 2013) 0.53 0.51 0.56 1.17 1.00 1.35 0.53 0.51 0.56 
rs2981578  1.24 1.21 1.26 (Meyer et al., 2013) 0.54 0.52 0.57 1.20 1.03 1.38 0.54 0.52 0.57 
rs2588809  1.08 1.05 1.11 (Michailidou et al., 2013) 0.53 0.51 0.55 1.31 1.07 1.59 0.53 0.51 0.55 
rs941764  1.06 1.04 1.09 (Michailidou et al., 2013) 0.54 0.51 0.56 1.26 1.08 1.46 0.54 0.51 0.56 
rs3803662  1.24 1.21 1.27 (Michailidou et al., 2013) 0.53 0.50 0.55 1.30 1.12 1.51 0.53 0.50 0.55 
rs4784227  1.19 1.09 1.31 (Long et al., 2010) 0.53 0.50 0.55 1.20 1.03 1.40 0.53 0.50 0.55 
rs13329835  1.08 1.05 1.10 (Michailidou et al., 2013) 0.53 0.51 0.55 1.23 1.02 1.49 0.53 0.51 0.55 





    0.57 0.54 0.59    0.59 0.57 0.62 
Established risk factors 




    0.63 0.60 0.66    
 
0.68 0.65 0.71 
Breast cancer 
susceptibility variants  
and Native American 
proportion combined 
 
    0.60 0.57 0.63    0.64 0.62 0.67 
Grand total      0.65 0.62 0.68    0.71 0.68 0.73 
Abbreviations: OR, odds ratio; Ref., reference.  
1For consistency with the publication by Fejerman et al. (Fejerman et al., 2014), was used here a 0-1 scale for Native American ancestry instead of the 1% 





Colombia is composed mainly of three racial groups: Europeans, Native Americans, 
and Africans. When the Spanish began the colonization of Colombia in 1525, they 
found several communities of Native Americans belonging to different tribes and 
linguistic groups. In the late fifteenth century, the population became more diverse 
with the arrival of Africans, who were brought to serve as labor source. The genetic 
characteristics of the Colombian population became more complex when the three 
ethnic groups began to mix, evolving to the modern Colombians (Ossa et al., 2016). 
This study examined for the first time the separate and combined contributions of 
established risk factors, genetic ancestry, and susceptibility variants to BC risk in this 
admixed population. The results showed that the risk effects conferred by common 
susceptibility variants are modified by Native American proportions. Also, Native 
American proportions can be used to predict BC risk as precisely as family history of 
BC. A new MRS was developed, showing that risk differences between Colombian 
women at high and low risk were as relevant as for women with European ancestry. 
From a total of 78 SNPs previously found to be associated with overall BC risk in 
Europeans, thirteen common variants were found be also associated with BC risk in 
Colombian women, and explained 4% of BC heritability in Colombia. Three variants 
were identified to be specifically associated with ER+ and ER- BC risk. Fejerman and 
colleagues performed a GWAS including 1,497 US Hispanic BC cases and 3,213 
controls and reported five identified associations at P-value<0.05 (rs10759243 
(KLF4), rs2981579 (FGFR2), rs941764 (CCDC88C), rs3803662 and rs4784227 
(TOX3) (Fejerman et al., 2014). On the contrary, five variants associated with BC in 




rs2588809 (RAD51B), rs13329835 (CDYL2), and rs2823093 (NRIP1)) were 
investigated in the same GWAS, but no associations were found. The distinct results 
may be due to differences between the study designs and samples sizes, as well as 
to dissimilarities between US Hispanics and Colombians in genetic ancestry and 
exposure to external factors. 
High European ancestry proportions have been associated with increased BC risk 
among Mexican women and US women of Latin American origin (Fejerman et al., 
2008; Fejerman et al., 2010; Slattery et al., 2012). These results are consistent with 
the present study, where the risk of developing BC decreased with the increasing 
Native American ancestry proportions. By local admixture mapping, two genetic 
regions associated with BC risk have been identified: a 6q25 region near to the ESR1 
gene and a region on 11p15 (Fejerman et al., 2012). Equivalently with the 
conclusions obtained for global ancestry, the magnitude of the association signals in 
the two identified regions decreased with increasing Native American proportions.  
A study that included 2,107 US Hispanic and Mexican women diagnosed with BC 
and 2,590 healthy controls had reported statistical interactions between Native 
American ancestry proportions and genetic variants associated with BC (Fejerman et 
al., 2013). The risk allele for three interacting variants rs13387042 (2q35), 
rs17157903 (RELN), and rs7696175 (TLR1) showed the strongest association in the 
group of women with the higher Native American proportions. Two statistical 
interactions were identified in the present Colombian study between global ancestry 
and associated variants. For rs941764 (CCDC88C), BC relative risks tended to 
increase with decreasing European ancestry proportions, while for rs3803662 




For the first time, a MRS was developed taking into account Native American 
proportions, well-established risk factors, and the 13 genetic variants associated with 
BC risk in Colombia. The MRS resulted in a good discriminative accuracy with an 
AUC between 0.65 and 0.71. An important finding was that the discriminative ability 
of established BC susceptibility factors such as family history of BC in first-degree 
female relatives was similar to the capacity of Native American ancestry proportions 
to discern Colombian women who developed BC from non-affected controls. A 
similar discriminative ability was also shown for the 13 genetic variants associated 
with BC risk in Colombia and Native American ancestry proportions. These results 
emphasize the importance of individual estimates of Native American ancestry 
proportions on the prediction of BC risk in Colombians and other Hispanic 
populations. Improvement in the quality of BC risk prediction model in Latino women 
may be achieved through more precise assessments of environmental exposures 
and by integrating newly identified susceptibility variants in future risk prediction 
models.  
Recent reports on known BC risk factors together with genomic profiles suggested 
insubstantial improvements in BC risk discrimination approach (Husing et al., 2012; 
Wacholder et al., 2010). More recently, polygenic risk scores based on large sets of 
susceptibility variants have been shown to be useful for BC risk discrimination in 
women of European ancestry from the general population, in males, and in female 
carriers of BRCA1 and BRCA2 mutations (Kuchenbaecker et al., 2017; Lecarpentier 
et al., 2017; Mavaddat et al., 2015). In the current study, a MRS was developed 
based on risk estimates from the literature combined with own genotype and risk 
factor data. The MRS combined established risk factors, 13 susceptibility variants, 




(AUC=0.61) increased to AUC=0.63 by considering Native American proportions, 
and further to AUC=0.65 by integrating recently identified BC susceptibility variants. 
The Colombian study has several weaknesses. Due to the limited size of the study 
including 1,022 BC patients and 1,023 healthy controls, only common BC 
susceptibility variants identified in the first large genome-wide association scans and 
fine-mapping studies in Europe were investigated. Many additional risk variants have 
been newly detected (Michailidou et al., 2017) and ongoing studies will identify other 
novel variants that should be investigated in future Colombian studies. A further 
limitation of this study was the presented missing genotypes for susceptibility variants 
and AIMs. Nevertheless, the ancestry proportion estimations were obtained with high 
accuracy (at least 99% correlation between estimates based on complete and 
imputed data). The number of participants was small to test the associations of 78 
variants. However the main goal of this study was to describe the associated risk 
effects, frequency, and potential interactions of these variants with genetic ancestry 
in the Colombian population. The majority of the study participants were recruited in 
the central area of Colombia, the Cundinamarca and Huila regions, and their 
representativeness for the whole country is questionable. One of the strengths of this 
study was the access to appropriate genotype data to investigate a timely 
hypothesis, which resulted in relevant findings for BC prevention in Latinas.  
Finally, the findings demonstrate that for BC risk prediction in Colombian women a 
MRS could be useful. A risk prediction model for Colombian women that combined 
established BC risk factors, newly identified susceptibility variants, and Native 
American proportions may constitute a powerful tool for clinical applications in 





The etiology of BC involves both non-genetic and genetic factors. Environmental and 
lifestyle factors such as age, use of menopausal hormone therapy, smoking, and BMI 
have been associated with the risk of developing BC. Genetic susceptibility 
determined mainly by family history and ethnic background have an important role in 
the risk of developing this disease (Dossus and Benusiglio, 2015). In recent years, 
novel variants robustly associated with BC risk have been identified in large-scale 
genetic association studies in women of European and Asian origin. However, few 
studies directed towards the identification of BC susceptibility variants have been 
conducted among Latin American and Hispanic populations. 
This thesis examined the contributions of genetic ancestry, established risk factors, 
and newly identified susceptibility variants to BC risk in Colombia. A total of 2,045 
participants from the Col-BCCC study were included in this analysis: 1,022 BC 
patients, and 1,023 healthy controls. BC patients were unselected for family history 
and age at BC diagnosis. European, Native American, and African ancestry 
proportion were quantified in each woman based on 30 AIMs, aiming to obtain the 
relationship between ancestry and BC risk. Seventy-eight previously identified 
common BC susceptibility variants were genotyped and associations of these 
variants with BC risk in the Colombian population were determined. To assess the 
interactions between the variants and ancestry proportions logistic regression models 
were applied. 
Native American proportions were lower in Colombian BC patients than in unaffected 
controls (P-value=5.2x10-16). This difference translated into an unadjusted 




(95% CI: 2.0-3.2). Associations with BC risk in Colombian women were obtained for 
thirteen variants, which in comparison with European women have partially different 
risk effects and allele frequencies. The risk effects of rs941764 (CCDC88C) and 
rs3803662 (TOX3) was controlled for ancestry proportions. One variant was 
associated with ER-, seven with ER+, and three with ER+ and ER- disease. The 
variance in BC liability due to susceptibility variants in European and Colombian 
women was estimated. Out of 13 variants associated with BC risk in Colombia, four 
explained a larger attributable heritability in Europe than in Colombia and nine 
revealed larger attributable heritability in Colombia than in Europe.  
AUCs with their corresponding 95% CIs were estimated for established risk factors, 
genetic ancestry, and common BC susceptibility variants based on risk estimates 
from the literature and own Colombian data. The discriminative ability to separate 
Colombian cases and controls of family history of BC in first-degree female relatives 
(AUC=0.58) and the combination of all 13 associated risk variants (AUC=0.57) were 
similar to the discriminative ability of Native American proportions (AUC=0.61). 
The findings demonstrate that individual ancestry proportions predict BC risk in 
Colombia as accurately as established BC risk factors. Combining Native American 
proportions, established risk factors, and newly identified genetic susceptibility 
variants could translate in promising clinical strategies on BC prevention in Latin 





Die Ätiologie von Brustkrebs (BC) beinhaltet sowohl nicht-genetische als auch 
genetische Faktoren. Umwelt- und Lebensstilfaktoren wie Alter, Anwendung der 
Hormontherapie in den Wechseljahren, Rauchen und Body-Mass-Index (BMI) 
wurden mit dem Risiko der Entwicklung von BC in Verbindung gebracht. Die 
genetische Anfälligkeit, die hauptsächlich durch die Familiengeschichte und den 
ethnischen Hintergrund bestimmt wird, spielt eine wichtige Rolle für das Risiko, an 
dieser Krankheit zu erkranken (Dossus and Benusiglio, 2015). In den letzten Jahren 
wurden in groß angelegten genetischen Assoziationsstudien bei Frauen 
europäischer und asiatischer Herkunft neuartige Varianten identifiziert, die stark mit 
dem BC-Risiko verbunden sind. Es wurden jedoch nur wenige Studien zur 
Identifizierung von BC-Anfälligskeitsvarianten unter lateinamerikanischen und 
hispanischen Bevölkerungen durchgeführt. 
Diese Arbeit untersuchte die Beiträge genetischer Abstammung, etablierte 
Risikofaktoren und neu identifizierte Anfälligkeitsvarianten für das BC-Risiko in 
Kolumbien. Insgesamt wurden 2.045 Teilnehmer einer kolumbianischen Brustkrebs 
Kontroll-Studie (Col-BCCC-Studie) in diese Analyse einbezogen: 1.022 BC-Patienten 
und 1.023 gesunde Kontrollpersonen. BC-Patienten wurden zum Zeitpunkt der BC-
Diagnose nicht nach Familienanamnese und Alter ausgewählt. Der Anteil 
europäischer, indianischer und afrikanischer Vorfahren wurde bei jeder Frau anhand 
von 30 abstammungs-informativen Markern (AIMs) quantifiziert, um die Beziehung 
zwischen Abstammung und BC-Risiko zu ermitteln. Achtundsiebzig zuvor 
identifizierte häufige BC-Anfälligkeitsvarianten wurden genotypisiert und 
Assoziationen dieser Varianten mit dem BC-Risiko in der kolumbianischen 




Abstammungsverhältnissen zu bewerten, wurden logistische Regressionsmodelle 
angewendet. 
Die Anteile der amerikanischen Ureinwohner waren bei kolumbianischen BC-
Patienten niedriger als bei nicht betroffenen Kontrollen (P-Wert = 5,2 × 10 –16). 
Dieser Unterschied führte zu einem nicht angepassten verringerten BC-Risiko von 
2,6% pro 1% Anstieg des Anteils der amerikanischen Ureinwohner (95% CI: 2,0-3,2). 
Assoziationen mit dem BC-Risiko bei kolumbianischen Frauen wurden für dreizehn 
Varianten erhalten, die im Vergleich zu europäischen Frauen teilweise 
unterschiedliche Risikoeffekte und Allel-Frequenzen aufweisen. Die Risikoeffekte von 
rs941764 (CCDC88C) und rs3803662 (TOX3) wurden hinsichtlich der 
Abstammungsverhältnisse kontrolliert. Eine Variante war mit Estrogenrezeptor 
negativ (ER-) assoziiert, sieben mit ER + und drei mit ER + und ER-. Die Varianz der 
BC-Haftung aufgrund von Anfälligkeitsvarianten bei europäischen und 
kolumbianischen Frauen wurde geschätzt. Von 13 Varianten, die mit dem BC-Risiko 
in Kolumbien assoziiert sind, erklärten vier eine größere zurechenbare Erblichkeit in 
Europa als in Kolumbien und neun zeigten eine größere zurechenbare Erblichkeit in 
Kolumbien als in Europa auf. 
Die Fläche unter der Kurve (AUC) mit ihren entsprechenden 95% CIs wurden auf der 
Grundlage von Risikoschätzungen aus der Literatur und eigenen kolumbianischen 
Daten für etablierte Risikofaktoren, genetischer Abstammung und häufiger BC-
Anfälligkeitsvarianten geschätzt. Die Unterscheidungsfähigkeit, kolumbianische Fälle 
und Kontrollen der Familiengeschichte von BC bei weiblichen Verwandten ersten 
Grades (AUC = 0,58) zu trennen, und die Kombination aller 13 assoziierten 
Risikovarianten (AUC = 0,57) waren ähnlich der Unterscheidungsfähigkeit der Anteile 




Die Ergebnisse zeigen, dass die individuellen Abstammungsanteile das BC-Risiko in 
Kolumbien genauso akkurat vorhersagen wie die etablierten BC-Risikofaktoren. Die 
Kombination von Anteilen der amerikanischen Ureinwohner, etablierten 
Risikofaktoren und neu identifizierten Varianten der genetischen Anfälligkeit könnte 
zu vielversprechenden klinischen Strategien zur BC-Prävention bei 
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Table S1: Primer sequences of the 78 SNPs under investigation 
# SNP-ID Forward primer 5´---- 3´ Reverse primer 5´---- 3´ Extension primer 5´---- 3´ 
1 rs11249433 ACGTTGGATGGGAAACATGGAATCCAAAAC ACGTTGGATGTGTGCTAAGGAGAAGCAACC ATCAGGGCTGGGTTTAA 
2 rs11552449 LC480 // Thermo Fisher assay (C__25619066_10) LC480 // Thermo Fisher assay (C__25619066_10) - 
3 rs616488 ACGTTGGATGTAGGGACAAACTAGCTCCTG ACGTTGGATGTCTTGGTGCTCTGAACAAGG GGGACTGGGGTACAGATGAGTG 
4 rs6678914 ACGTTGGATGGTGTCATCTTGTGTGTTTGG ACGTTGGATGCTCCCCACTTTAGATGGCAC TTTTAGATGGCACCTTCTTA 
5 rs4245739 ACGTTGGATGAGCATAATGGTAGTACGAAC ACGTTGGATGAACATTCTCTGACAGGTTGG TTCAAATAATGTGGTAAGTGAAC 
6 rs12710696 ACGTTGGATGTCCGTCTACAGGAATGATGC ACGTTGGATGAAGAAGGCGCCTCACATAGT GATTAATCATCAGGCCC 
7 rs4849887 ACGTTGGATGTTAAACCCTGGGTGTGATGC ACGTTGGATGTGGTTGAGGGGATTACCTAC GGGGATTCCAGCTGTGATCTGGCAATG 
8 rs1550623 ACGTTGGATGGTTAAAGAGCTTTGAATTCCC ACGTTGGATGGGAATTCTTTGTGCAAGGTG AGTTATAGAGAAACACAGAATTCTTA 
9 rs2016394 ACGTTGGATGTCTGTTCAGGAATCTTCCCG ACGTTGGATGTCTCTCCCCAAAGAGAGTCC TTACAGAGAGTCCTGGAAGGG 
10 rs16857609 ACGTTGGATGCTCAAGAAAGGGATGCCAAC ACGTTGGATGCAGAGACCGGAAGGTATTCT TGTCTGGGAGACTTC 
11 rs4442975 ACGTTGGATGAGTGCAGGTCACTAATATAG ACGTTGGATGGTATCCTACAGGTATGGAGC TGATTGCAGGTCACTAATATAGTCTATT 
12 rs4973768 ACGTTGGATGCACTGTCTCTCAATGAATGC ACGTTGGATGACTCCATTTAAGAGCAAAGG TGAGAGCAAAGGTAACTCATGTTTA 
13 rs12493607 ACGTTGGATGATGTATATGACCTCAAGGGC ACGTTGGATGGACTCCCTATTAGTTGACCC GGAAGGCTACCTGGAATTGTTAAG 
14 rs6762644 ACGTTGGATGGGATGGGATGTAAAAGAGGC ACGTTGGATGATTCCTGAGGTCCCAAATCG AAATCGCATCCTGCC 
15 rs9790517 ACGTTGGATGTACCATGCTAAGCACTTTCC ACGTTGGATGTAACCCCATGTCTTGGTTTC GGGGTCTTCCTTAGTAAAGTGAG 
16 rs6828523 ACGTTGGATGGGCATGGATTTAATAACGAGG ACGTTGGATGTCTCCATACCCACTTTCTCC CTTCATAACGAGGTGTTAATATTGGTT 
17 rs10941679 ACGTTGGATGGCCAGTAAAATGTGGGATGC ACGTTGGATGCTTCTTTGAGCAATGATCGG ATTCTGCTGTGTTCTTTCCA 
18 rs10069690 ACGTTGGATGCTGTTTGAAACGGGTTCCTG ACGTTGGATGACCCCGTCATCTGAGGAGA TCACCCGGGATCCTCATGCCA 
19 rs2736108 LC480 // Thermo Fisher assay (C__26414910_20) LC480 // Thermo Fisher assay (C__26414910_20) - 
20 rs3215401 ACGTTGGATGGCATTTCAGTGTTTGCCGAC ACGTTGGATGCTCCGGGTTGCTCAAGTTTG CCGAAGTTTCTCGCCCC 
21 rs2242652 ACGTTGGATGAGGCTCTGAGGACCACAAGA ACGTTGGATGACAGCAGGACACGGATCCAG TCTTAGGACCACAAGAAGCAGC 
22 rs889312 ACGTTGGATGGAGATGATCTCTGAGATGCC ACGTTGGATGGACACAGATTTATGGGAAGG GGCCTGCTGGAGAAAGG 
23 rs1353747 ACGTTGGATGTTACAATGAAGCTGGGAGTC ACGTTGGATGACTTGAGGCTCAGGCTTTGA CCTCGTCCCCTCTGAGGTTCGGC 
24 rs10472076 ACGTTGGATGCCTCATGTCCAAGCTCTTTG ACGTTGGATGAGGTCCAGCCGCCAAGTTAA AGCAGCTGTCCAGACATC 
25 rs1432679 ACGTTGGATGACTTCGCAATTGCCACCAAG ACGTTGGATGGTGAGGGCTACATCATGCAG AAAAGTGGGCTGGTCA 
26 rs204247 ACGTTGGATGTCTGCTTCAGCTGCAATTAG ACGTTGGATGCACAGACAATGCTACCTCTC TTGAAAATGCTACCTCTCTTTAAATAA 
27 rs11242675 ACGTTGGATGTCTAGAGGAGACTACAACGC ACGTTGGATGAGCAAACAGTGTCACCGTCC TTGCTGAAGGGTCTAGATAC 
28 rs17530068 ACGTTGGATGCTTATAACCAGTGTGGAAAG ACGTTGGATGTCCTGTGTTGTGTGTTGACG ACTCAGAGAATTTGTTTAGCCCCAT 
29 rs2046210 ACGTTGGATGTGAAACCATCAGGGTGCCTC ACGTTGGATGCCTCACACATACATACAGTC CCCGCACACATACATACAGTCACATAC 




31 rs9693444 ACGTTGGATGCAAAGGCTATGCTTCTCCTC ACGTTGGATGGGCTTAGAAGACTTTGCCAG GCTAGGCTTCTCCTCTTTGCCCA 
32 rs6472903 ACGTTGGATGTGAAAAGACAAGCTGCCAGG ACGTTGGATGGACCTCCAAAAACTGTCTTC CAATCAGTCAATATTTACTGAATAC 
33 rs13281615 ACGTTGGATGCCTGGAATCTAGGGATGTAG ACGTTGGATGAACCCCCTACTCAGAATATC GAATATCTGCGTTCTGC 
34 rs11780156 ACGTTGGATGACTGGTCCCAGATAAGGTGA ACGTTGGATGCTCACTTACGAAGGTATGGG CATGGAACACAGCTAC 
35 rs1011970 ACGTTGGATGAGGGAAGATACAGGTGGAAC ACGTTGGATGCTCTAGAACTGATAGGGAGC GAGTGTGGAACTGGGCCAGTGTTT 
36 rs10816625 ACGTTGGATGAGGTTACATTCACAGAGGTC ACGTTGGATGCACGTGACATCACTTCAAAC TTTACAAATAAACGGTCTATTTATTCA 
37 rs676256 ACGTTGGATGGGATACAACATGGGTTTGCG ACGTTGGATGAAGAGCTAGAGCAGCACTTC ATGGGTTTGCGGGCACA 
38 rs865686 ACGTTGGATGGTCTCATTAGCCAGGAAACC ACGTTGGATGCGAGACTGTGGTATTCTAGG GACCGGAAACCAAGGTTTCCAAC 
39 rs10759243 ACGTTGGATGTGGGTAAACACAGCAAAATG ACGTTGGATGCCCAGCCCCTTTTTATTTTC GGGTAGATAATGTGTGACAGTGTATA 
40 rs11814448 ACGTTGGATGTTGAGCCCCAGAAGCTAATT ACGTTGGATGAAGTATGTGAATGTCTCACC GCTAATTTTCTTTTCAGTTATTATG 
41 rs7072776 ACGTTGGATGGCAGTACTCACACTTGGTAG ACGTTGGATGAGACCACTAAGTAGATTGGG GGAACACTAAGTAGATTGGGCTTCTC 
42 rs10995190 ACGTTGGATGCAATGGTTGTGTCCAAGTGC ACGTTGGATGTGGCTCATGACTTGAACCAC GGGTGTTGTGTCCAAGTGCATATTGA 
43 rs704010 ACGTTGGATGTACTGCCACGTCTTACAACC ACGTTGGATGCTGGGCCTTATTATCTCTGC CTGCGACCTGACCTGAAAATAGC 
44 rs7904519 ACGTTGGATGAAGAAGGGTGGTTAGACAGG ACGTTGGATGGCAGAGCGTGGACATTTTTC CCTAGCTGAATGCCGACC 
45 rs11199914 ACGTTGGATGACAGTGGGTGGAATAAGCAG ACGTTGGATGGGAGCTGCGTAGATATCAAG CAATACCACATTCAAGTCCTGT 
46 rs35054928 ACGTTGGATGCTCTCACAATCCTCCAAAGC ACGTTGGATGTCCCAGAAAGCCTACATTCG GGGAGAAAGCCTACATTCGTGGGAGCCG 
47 rs2981579 ACGTTGGATGGGTTGAAGGTCACTTGCTTG ACGTTGGATGTTCATATTTCCACCTGCCCG ATGGATACGACCTCTG 
48 rs2981578 ACGTTGGATGGTGAGAGGTAGTGACTCTTC ACGTTGGATGCACAGTTAACCTTTCTTCCC TTCCCTGCTCCAAAC 
49 rs3750817 ACGTTGGATGGGGTTGTCTTGAGACAGTTG ACGTTGGATGGCTGGTTTGGCAACGTAAAG GCAAAAGGGTTTGGAAA 
50 rs11200014 ACGTTGGATGTGTTTTCGGCTGTTCATGAC ACGTTGGATGAATACACGTGTTGGGACCAG GGGACCAGAGAGAAAA 
51 rs2420946 ACGTTGGATGCTCATGGAAACTATAAACCC ACGTTGGATGCTGCTCAACCTGGGATCTGT GGTGCGGGATCTGTGGATGC 
52 rs3817198 ACGTTGGATGTCTCACCTGATACCAGATTC ACGTTGGATGCTTGAGCTTCCCTAGTGGAG GGGCTGGCTGACTCTAGTGAAATGAGC 
53 rs614367 ACGTTGGATGTCCTTGGCTTTTTCCTCCAG ACGTTGGATGGGGTTTGACAGGCTTCTTGG GCTTCTCTGCAACTC 
54 rs3903072 ACGTTGGATGCATTCATCCACCATATCCCG ACGTTGGATGCTTCTTTAGTCCTCTTCCAG AAGGAGTTCTGTTCTGTGCTG 
55 rs554219 ACGTTGGATGAGGTGCTGGGTTGACTGTG ACGTTGGATGTGTTGTGTGATTCCACTCCC CGAGAGCAGGGAAATCCTCAC 
56 rs11820646 ACGTTGGATGTGCTCCTGGAAAGAAGGTAG ACGTTGGATGGTCATATGACTCTGGAGGTG GTGGGACTTGAAATCAAAAGACA 
57 rs12422552 ACGTTGGATGTGAGGGTAACATCGCGGTAG ACGTTGGATGGACACTGATGGAAAATCGTC AGAGCATCGCGGTAGTCAGTCCA 
58 rs17356907 ACGTTGGATGTGCTGCCAGATGATCACTTC ACGTTGGATGTTGTCAGATCCAGCAGAGAC TAATGGGGATTAGATGGT 
59 rs1292011 ACGTTGGATGACTCCCAAGATCCTAAGTCC ACGTTGGATGCAAGTACACCGCTTGCCTTC CATCCTGCTGCCTCTGA 
60 rs2236007 ACGTTGGATGAGGCTGGGCGTGTGGATGT ACGTTGGATGAAAGACAGTGTCCCTGAGGC GGATGTGCAGCGTCT 
61 rs999737 ACGTTGGATGGGTCCCGTTCACATGATATG ACGTTGGATGCTTTTTCAGGTCCTGGAATG TCCGGTCACATGATATGAATGGGGC 
62 rs2588809 ACGTTGGATGTAAGGTGAACAGTGAGCCAG ACGTTGGATGCTTGCCTCAACTTGACTTGG GGAGACTGGTGAATGAGATTAGGT 
63 rs941764 ACGTTGGATGTCCAACAGTCTGGCAGCATC ACGTTGGATGTGTGTGAGACTTCCTTGTGC GGGGTTCGGAATGAGCCTGAC 
64 rs17817449 ACGTTGGATGCCCTTTGTGTTTCAGCTTGG ACGTTGGATGGAGTGCACCAAATTCAAACC CTTAAGCTTGGCACACAGAAAC 
65 rs11075995 ACGTTGGATGTGCTTTGAGTATACTGGGGC ACGTTGGATGGCCATGAGCAGCAACTCTAA CTCTCACTATACTGGTTACTTTCT 
66 rs3803662 ACGTTGGATGTTTTCTCTCCTTAATGCCTC ACGTTGGATGGCTGAAGACCCAGTACTTTC CAGTACACAGTTTTATTCTTCGCTAAG 
67 rs4784227 ACGTTGGATGTTAACAGCCAACTCTTTGGG ACGTTGGATGGAAATTGGTCATGATGGGAG TGGGAGTATTTACATCACAATAATC 
68 rs13329835 ACGTTGGATGCCTAGCAACACACCAGTGAG ACGTTGGATGGAGCTTTGGGTATGTCATGG ATGTCATGGATCTCTCTG 




70 rs1436904 ACGTTGGATGTGCAAGACTATGTGTGCCTC ACGTTGGATGAGACAGGAGACAGATTCTGC CCCTGTGTCTCATTCCTCA 
71 rs527616 ACGTTGGATGTTACACGAGACTGAGCCAAC ACGTTGGATGATGGAAATGCCCCTTAGGAC AGGACAAGTCTAAACTAGG 
72 rs8170 ACGTTGGATGAGTTTCGCCATGCAGTTGTG ACGTTGGATGTGGATACCAAGGGTACCAG GATCCCAAGGGTACCAGCTACAA 
73 rs2363956 ACGTTGGATGAGCCATGCAGAGGTGACAAC ACGTTGGATGGTTTGTCCACAGTTTCAAGG CCTGGGTCAGCCTCC 
74 rs4808801 LGC (KASP allelic discrimination) LGC (KASP allelic discrimination) - 
75 rs3760982 ACGTTGGATGTACACCAGCACACAGTAACG ACGTTGGATGATGTGGTCGTTTGTGGAAGG CAAGTAACGCAAAACACATA 
76 rs2284378 ACGTTGGATGAGCATCGTTTGGTCAGTGTG ACGTTGGATGCCCCCCCAGATGATTTTATG TGGGCTGGACTAAGG 
77 rs2823093 ACGTTGGATGTCAAGTCAAGGAACAAAGGG ACGTTGGATGAAGTGCTGGAGGAAGTCACG GACGGGTTCAGGAGACA 














Major/Minor MAF OR AF1 95% CI OR1 95% CI P-value2 ORadj.3 95% CI P-value2 
Reference 
EUROPEANS 
rs11249433 1p11.2 EMBP1 A/G 0.40 1.09 0.27 0.24 0.29 1.09 0.95 1.25 0.21 1.02 0.87 1.19 0.84 
(Michailidou et al., 
2013) 
rs11552449 1p13.2 DCLRE1B C/T 0.17 1.07 0.39 0.36 0.42 0.91 0.80 1.03 0.13 0.92 0.79 1.07 0.27 
(Michailidou et al., 
2013) 
rs616488 1p36.22 PEX14  A/G 0.33 0.94 0.40 0.37 0.43 0.92 0.81 1.05 0.24 0.95 0.81 1.11 0.55 
(Michailidou et al., 
2013) 
rs6678914 1q32.1 LGR6  G/A 0.41 0.904 0.30 0.27 0.32 1.09 0.95 1.25 0.21 1.10 0.93 1.29 0.26 
(Garcia-Closas et al., 
2013b) 
rs4245739 1q32.1 MDM4  A/C 0.26 1.144 0.25 0.22 0.27 1.04 0.90 1.20 0.62 1.00 0.84 1.19 0.98 
(Garcia-Closas et al., 
2013b) 
rs12710696 2p24.1 OSR1 G/A 0.36 1.104 0.32 0.29 0.35 0.96 0.84 1.10 0.56 0.96 0.82 1.12 0.59 
(Garcia-Closas et al., 
2013b) 
rs4849887 2q14.1 INHBB C/T 0.10 0.91 0.11 0.09 0.13 0.85 0.69 1.04 0.11 0.88 0.69 1.12 0.29 
(Michailidou et al., 
2013) 
rs1550623 2q31.1 CDC7 A/G 0.16 0.94 0.21 0.19 0.24 1.00 0.86 1.16 0.96 0.99 0.83 1.18 0.90 
(Michailidou et al., 
2013) 
rs2016394 2q31.1 DLX2 G/A 0.48 0.95 0.47 0.44 0.50 0.97 0.86 1.10 0.62 0.97 0.83 1.12 0.65 
(Michailidou et al., 
2013) 
rs16857609 2q35 DIRC3 C/T 0.26 1.08 0.38 0.35 0.41 0.98 0.86 1.12 0.79 0.92 0.78 1.07 0.28 
(Michailidou et al., 
2013) 
rs4442975 2q35 IGFBP5 G/T 0.49 0.87 0.65 0.62 0.68 0.82 0.65 0.96 0.01 0.82 0.62 0.99 0.03 
(Ghoussaini et al., 
2014) 
rs4973768 3p24.1 SLC4A7 C/T 0.47 1.10 0.62 0.59 0.65 1.02 0.89 1.14 0.77 1.03 0.86 1.16 0.74 
(Michailidou et al., 
2013) 
rs12493607 3p24.1 TGFBR2 G/C 0.35 1.06 0.27 0.25 0.30 0.96 0.84 1.10 0.56 0.93 0.79 1.09 0.38 
(Michailidou et al., 
2013) 
rs6762644 3p26.1 EGOT/ITPR1 A/G 0.40 1.07 0.32 0.29 0.35 1.10 0.97 1.26 0.14 1.10 0.94 1.29 0.23 
(Michailidou et al., 
2013) 
rs9790517 4q24 TET2 C/T 0.23 1.05 0.34 0.31 0.37 0.94 0.83 1.08 0.39 0.97 0.83 1.14 0.72 
(Michailidou et al., 
2013) 
rs6828523 4q34.1 ADAM29 C/A 0.13 0.90 0.18 0.15 0.20 0.91 0.77 1.07 0.25 0.89 0.73 1.08 0.25 
(Michailidou et al., 
2013) 
rs10941679 5p12 MRPS30 A/G 0.25 1.13 0.33 0.30 0.36 1.12 0.98 1.27 0.10 1.08 0.92 1.26 0.37 
(Michailidou et al., 
2013) 
rs10069690 5p15.33 TERT C/T 0.26 1.06 0.23 0.20 0.25 1.11 0.96 1.28 0.17 1.03 0.87 1.23 0.73 
(Michailidou et al., 
2013) 
rs2736108 5p15.33 TERT C/T 0.29 0.94 0.21 0.18 0.23 1.03 0.88 1.19 0.73 1.05 0.87 1.26 0.61 
(Bojesen et al., 
2013b) 
rs3215401 5p15.33 TERT -/C 0.30 0.94 0.22 0.19 0.24 1.03 0.89 1.20 0.68 1.06 0.89 1.27 0.52 
(Bojesen et al., 
2013b) 
rs2242652 5p15.33 TERT G/A 0.20 1.06 0.14 0.12 0.16 1.15 0.97 1.37 0.11 1.02 0.83 1.25 0.87 
(Bojesen et al., 
2013b) 
rs889312 5q11.2 MAP3K1 A/C 0.28 1.12 0.43 0.40 0.46 0.97 0.86 1.10 0.67 1.13 0.97 1.31 0.12 
(Michailidou et al., 
2013) 
rs1353747 5q11.2 PDE4D T/G 0.10 0.92 0.11 0.09 0.13 0.94 0.78 1.13 0.51 1.00 0.80 1.26 0.97 





rs10472076 5q11.2 RAB3C T/C 0.38 1.05 0.28 0.26 0.31 1.12 0.98 1.28 0.10 1.06 0.91 1.24 0.47 
(Michailidou et al., 
2013) 
rs1432679 5q33.3 EBF1 T/C 0.43 1.07 0.62 0.59 0.65 1.08 0.96 1.20 0.18 1.12 0.97 1.25 0.10 
(Michailidou et al., 
2013) 
rs204247 6p23 RANBP9 A/G 0.43 1.05 0.46 0.43 0.49 1.06 0.94 1.20 0.33 1.08 0.93 1.25 0.32 
(Michailidou et al., 
2013) 
rs11242675 6p25.3 FOXQ1 T/C 0.39 0.94 0.49 0.46 0.52 0.94 0.84 1.07 0.35 0.95 0.83 1.10 0.52 
(Michailidou et al., 
2013) 
rs17530068 6q14.1 FAM46A A/G 0.22 1.05 0.25 0.23 0.28 1.08 0.94 1.24 0.31 1.01 0.85 1.19 0.93 
(Michailidou et al., 
2013) 
rs2046210 6q25.1 ESR1/CCDC170 G/A 0.34 1.08 0.26 0.24 0.29 1.18 1.03 1.36 0.02 1.30 1.11 1.54 0.002 
(Michailidou et al., 
2013) 
rs720475 7q35 ARHGEF5/NOBOX G/A 0.25 0.94 0.19 0.16 0.21 0.98 0.83 1.14 0.76 0.96 0.79 1.16 0.67 
(Michailidou et al., 
2013) 
rs9693444 8p12 DUSP4 C/A 0.32 1.07 0.28 0.25 0.31 1.00 0.87 1.15 0.97 1.00 0.84 1.18 0.99 
(Michailidou et al., 
2013) 
rs6472903 8q21.11 HNF4G T/G 0.18 0.91 0.07 0.06 0.09 1.23 0.98 1.56 0.07 1.13 0.86 1.50 0.38 
(Michailidou et al., 
2013) 
rs13281615 8q24.21 POU5F1B A/G 0.41 1.09 0.57 0.54 0.60 1.02 0.89 1.14 0.74 0.94 0.76 1.09 0.45 
(Michailidou et al., 
2013) 
rs11780156 8q24.21 PVT1/MYC C/T 0.16 1.07 0.18 0.16 0.21 1.09 0.93 1.28 0.28 1.12 0.93 1.36 0.23 
(Michailidou et al., 
2013) 
rs1011970 9p21.3 CDKN2A/B G/T 0.17 1.06 0.37 0.34 0.40 0.99 0.88 1.13 0.93 1.06 0.92 1.23 0.41 
(Michailidou et al., 
2013) 
rs10816625 9q31.2 KLF4 A/G 0.06 1.12 0.15 0.13 0.17 1.09 0.92 1.29 0.31 1.06 0.87 1.30 0.57 (Orr et al., 2015b) 
rs676256 9q31.2 KLF4 A/G 0.38 0.90 0.32 0.29 0.35 0.96 0.84 1.11 0.61 0.88 0.74 1.03 0.12 (Orr et al., 2015b) 
rs865686 9q31.2 KLF4 T/G 0.38 0.89 0.36 0.33 0.39 0.93 0.82 1.06 0.27 0.91 0.78 1.06 0.22 
(Michailidou et al., 
2013) 
rs10759243 9q31.2 KLF4 C/A 0.39 1.06 0.43 0.40 0.46 1.15 1.01 1.30 0.03 1.18 1.01 1.37 0.03 
(Michailidou et al., 
2013) 
rs11814448 10p12.31 DNAJC1  A/C 0.02 1.26 0.06 0.04 0.07 0.94 0.72 1.22 0.62 1.26 0.92 1.74 0.16 
(Michailidou et al., 
2013) 
rs7072776 10p12.31 MLLT10/DNAJC1  G/A 0.29 1.07 0.37 0.34 0.40 0.98 0.86 1.11 0.71 1.01 0.87 1.18 0.90 
(Michailidou et al., 
2013) 
rs10995190 10q21 ZNF365  G/A 0.16 0.86 0.09 0.07 0.10 0.96 0.77 1.20 0.73 1.03 0.79 1.36 0.81 
(Michailidou et al., 
2013) 
rs704010 10q22.3 ZMZ1  C/T 0.38 1.08 0.44 0.41 0.47 0.98 0.86 1.11 0.72 1.02 0.88 1.18 0.82 
(Michailidou et al., 
2013) 
rs7904519 10q25.2 TCF7L2  A/G 0.46 1.06 0.33 0.30 0.35 1.14 1.00 1.29 0.05 1.12 0.96 1.30 0.16 
(Michailidou et al., 
2013) 
rs11199914 10q26.12 FGFR2 C/T 0.32 0.95 0.43 0.40 0.46 0.79 0.69 0.89 0.0002 0.77 0.66 0.89 0.0007 
(Michailidou et al., 
2013) 
rs35054928 10q26.13 FGFR2 -/C 0.44 1.27 0.39 0.36 0.42 1.20 1.06 1.36 0.005 1.17 1.00 1.35 0.05 (Meyer et al., 2013) 
rs2981579 10q26.13 FGFR2  G/A 0.40 1.27 0.39 0.36 0.42 1.21 1.06 1.37 0.003 1.17 1.00 1.35 0.05 
(Michailidou et al., 
2013) 
rs2981578 10q26.13 FGFR2 T/C 0.49 1.24 0.46 0.43 0.49 1.24 1.10 1.41 0.0005 1.20 1.03 1.38 0.02 (Meyer et al., 2013) 
rs3750817 10q26.13 FGFR2 C/T 0.39 0.785 0.41 0.38 0.44 0.83 0.73 0.94 0.005 0.89 0.76 1.03 0.12 
(Prentice et al., 
2009a) 
rs11200014 10q26.13 FGFR2 G/A 0.39 1.28 0.36 0.33 0.39 1.14 1.01 1.30 0.03 1.06 0.92 1.23 0.43 
(Barnholtz-Sloan et 
al., 2010) 




rs3817198 11p15.5 LSP1 T/C 0.31 1.07 0.19 0.16 0.21 1.23 1.06 1.43 0.008 1.14 0.95 1.37 0.15 
(Michailidou et al., 
2013) 
rs614367 11q13.3 MYEOV/CCND1 C/T 0.15 1.21 0.06 0.04 0.07 1.34 1.05 1.73 0.02 1.15 0.85 1.57 0.36 
(Michailidou et al., 
2013) 
rs3903072 11q13.1 CFL1/OVOL1 G/T 0.47 0.95 0.32 0.29 0.35 1.02 0.90 1.17 0.75 0.91 0.78 1.07 0.26 
(Michailidou et al., 
2013) 
rs554219 11q13.3 CCND1 C/G 0.12 1.27 0.06 0.05 0.08 1.40 1.09 1.79 0.008 1.20 0.89 1.62 0.23 (French et al., 2013b) 
rs11820646 11q24.3 BARX2 C/T 0.41 0.95 0.48 0.45 0.51 0.94 0.83 1.07 0.35 0.89 0.77 1.03 0.13 
(Michailidou et al., 
2013) 
rs12422552 12p13.1 ATF7IP G/C 0.26 1.05 0.23 0.20 0.25 1.06 0.92 1.23 0.40 1.14 0.96 1.36 0.13 
(Michailidou et al., 
2013) 
rs17356907 12q22 NTN4  A/G 0.30 0.91 0.38 0.35 0.41 0.94 0.83 1.07 0.38 0.93 0.80 1.09 0.37 
(Michailidou et al., 
2013) 
rs1292011 12q24.21 MED13L/TBX3 A/G 0.42 0.92 0.41 0.38 0.44 0.96 0.85 1.09 0.55 0.96 0.82 1.11 0.57 
(Michailidou et al., 
2013) 
rs2236007 14q13.3 PAX9 G/A 0.21 0.93 0.15 0.13 0.17 0.88 0.74 1.04 0.13 0.88 0.72 1.08 0.22 
(Michailidou et al., 
2013) 
rs999737 14q24.1 RAD51B  C/T 0.23 0.92 0.14 0.12 0.16 0.94 0.78 1.12 0.49 0.84 0.68 1.04 0.12 
(Michailidou et al., 
2013) 
rs2588809 14q24.1 RAD51B  C/T 0.16 1.08 0.16 0.14 0.18 1.28 1.09 1.51 0.003 1.31 1.07 1.59 0.008 
(Michailidou et al., 
2013) 
rs941764 14q32.11 CCDC88C A/G 0.34 1.06 0.42 0.39 0.45 1.21 1.06 1.37 0.004 1.26 1.08 1.46 0.003 
(Michailidou et al., 
2013) 
rs17817449 16q12.2 FTO  T/G 0.40 0.93 0.27 0.24 0.30 0.99 0.86 1.14 0.89 0.93 0.79 1.10 0.41 
(Michailidou et al., 
2013) 
rs11075995 16q12.2 FTO T/A 0.24 1.114 0.36 0.33 0.39 0.95 0.84 1.08 0.41 0.99 0.85 1.15 0.86 
(Garcia-Closas et al., 
2013b) 
rs3803662 16q12.1 TOX3 G/A 0.26 1.24 0.43 0.40 0.46 1.21 1.07 1.37 0.003 1.30 1.12 1.51 0.0007 
(Michailidou et al., 
2013) 
rs4784227 16q12.1 TOX3 C/T 0.25 1.19 0.35 0.32 0.38 1.21 1.07 1.38 0.003 1.20 1.03 1.40 0.02 (Long et al., 2010) 
rs13329835 16q23.2 CDYL2  A/G 0.22 1.08 0.17 0.15 0.20 1.22 1.04 1.43 0.02 1.23 1.02 1.49 0.03 
(Michailidou et al., 
2013) 
rs6504950 17q22 STXBP4 G/A 0.28 0.94 0.17 0.15 0.20 1.17 1.00 1.37 0.05 1.14 0.95 1.37 0.17 
(Michailidou et al., 
2013) 
rs1436904 18q11.2 CHST9  T/G 0.40 0.96 0.45 0.42 0.48 0.87 0.76 0.98 0.02 0.90 0.78 1.05 0.18 
(Michailidou et al., 
2013) 
rs527616 18q11.2 AQP4 G/C 0.38 0.95 0.74 0.71 0.77 0.94 0.78 1.08 0.40 0.99 0.80 1.14 0.88 
(Michailidou et al., 
2013) 
rs8170 19p13.11 BABAM1=MERIT40  G/A 0.19 1.04 0.09 0.08 0.11 1.16 0.95 1.43 0.15 1.07 0.84 1.37 0.58 
(Michailidou et al., 
2013) 
rs2363956 19p13.11 ANKLE1 C/A 0.49 1.01 0.60 0.57 0.63 0.95 0.81 1.07 0.42 0.94 0.77 1.09 0.48 
(Antoniou et al., 
2010b) 
rs4808801 19p13.11 ELL A/G 0.35 0.93 0.32 0.29 0.35 0.96 0.84 1.10 0.59 0.95 0.81 1.11 0.51 
(Michailidou et al., 
2013) 
rs3760982 19q13.31 KCNN4/LYPD5 G/A 0.46 1.06 0.31 0.28 0.34 1.14 1.00 1.29 0.06 1.09 0.93 1.27 0.29 
(Michailidou et al., 
2013) 
rs2284378 20q11.22 RALY  C/T 0.31 1.144 0.32 0.29 0.35 1.04 0.92 1.19 0.52 1.00 0.85 1.17 0.99 (Siddiq et al., 2012) 
rs2823093 21q21.1 NRIP1  G/A 0.27 0.92 0.32 0.29 0.34 0.77 0.67 0.89 0.0003 0.84 0.71 0.99 0.04 
(Michailidou et al., 
2013) 
rs6001930 22q13.1 MKL1 T/C 0.11 1.12 0.11 0.09 0.13 0.99 0.81 1.20 0.92 0.96 0.76 1.21 0.73 
(Michailidou et al., 
2013) 




*Genome assembly GRCh37. 
1AFs and ORs different in Europe and Colombia (non-overlapping confidence intervals) are marked in bold. 
2P-values smaller than 0.05 are marked in bold, P-values smaller than 0.05 after multiplicity adjustment using multiple permutation are underlined. 
3OR adjusted for age, family history of breast cancer in first-degree female relatives, oral contraceptive use, menopausal status combined with postmenopausal hormone 
















Major/Minor  MAF  OR AF1 95% CI OR 95% CI P-value2 ORadj.1,3 95 % CI P-value2 
Reference 
ASIANS 
rs11249433 1p11.2 EMBP1 A/G 0.03 1.16 0.27 0.24 0.29 1.09 0.95 1.25 0.21 1.02 0.87 1.19 0.84 (Zheng et al., 2013) 
rs11552449 1p13.2 DCLRE1B T/C 0.39 0.97 0.61 0.58 0.64 1.09 0.97 1.20 0.13 1.08 0.93 1.21 0.27 (Zheng et al., 2013) 
rs616488 1p36.22 PEX14  A/G 0.31 0.94 0.40 0.37 0.43 0.92 0.81 1.05 0.24 0.95 0.81 1.11 0.55 (Zheng et al., 2013) 
rs6678914 1q32.1 LGR6  G/A 0.24 0.964 0.30 0.27 0.32 1.09 0.95 1.25 0.21 1.10 0.93 1.29 0.26 
(Garcia-Closas et 
al., 2013b) 
rs4245739 1q32.1 MDM4  A/C 0.06 0.974 0.25 0.22 0.27 1.04 0.90 1.20 0.62 1.00 0.84 1.19 0.98 
(Garcia-Closas et 
al., 2013b) 
rs12710696 2p24.1 OSR1 G/A 0.33 1.054 0.32 0.29 0.35 0.96 0.84 1.10 0.56 0.96 0.82 1.12 0.59 
(Garcia-Closas et 
al., 2013b) 
rs4849887 2q14.1 INHBB C/T 0.18 0.93 0.11 0.09 0.13 0.85 0.69 1.04 0.11 0.88 0.69 1.12 0.29 (Zheng et al., 2013) 
rs1550623 2q31.1 CDCA7 A/G 0.01 0.79 0.21 0.19 0.24 1.00 0.86 1.16 0.96 0.99 0.83 1.18 0.90 (Zheng et al., 2013) 
rs2016394 2q31.1 DLX2 G/A 0.19 0.99 0.47 0.44 0.50 0.97 0.86 1.10 0.62 0.97 0.83 1.12 0.65 (Zheng et al., 2013) 
rs16857609 2q35 DIRC3 T/C 0.41 0.93 0.62 0.59 0.65 1.02 0.88 1.14 0.79 1.08 0.93 1.22 0.28 (Zheng et al., 2013) 
rs4442975 2q35 IGFBP5 G/T 0.13 0.94 0.65 0.62 0.68 0.82 0.65 0.96 0.01 0.82 0.62 0.99 0.03 
(Ghoussaini et al., 
2014) 
rs4973768 3p24.1 SLC4A7 C/T 0.19 1.11 0.62 0.59 0.65 1.02 0.89 1.14 0.77 1.03 0.86 1.16 0.74 (Zheng et al., 2013) 
rs12493607 3p24.1 TGFBR2 C/G 0.33 0.95 0.73 0.70 0.75 1.04 0.90 1.16 0.56 1.07 0.91 1.21 0.38 (Zheng et al., 2013) 
rs6762644 3p26.1 EGOT/ITPR1 A/G 0.08 1.03 0.32 0.29 0.35 1.10 0.97 1.26 0.14 1.10 0.94 1.29 0.23 (Zheng et al., 2013) 
rs9790517 4q24 TET2 T/C 0.39 0.98 0.66 0.63 0.69 1.06 0.92 1.17 0.39 1.03 0.86 1.17 0.72 (Zheng et al., 2013) 
rs6828523 4q34.1 ADAM29 A/C 0.24 0.93 0.82 0.80 0.85 1.09 0.93 1.23 0.25 1.11 0.92 1.27 0.25 (Zheng et al., 2013) 
rs10941679 5p12 MRPS30 A/G 0.48 1.08 0.33 0.30 0.36 1.12 0.98 1.27 0.10 1.08 0.92 1.26 0.37 (Zheng et al., 2013) 
rs10069690 5p15.33 TERT C/T 0.22 1.05 0.23 0.20 0.25 1.11 0.96 1.28 0.17 1.03 0.87 1.23 0.73 (Zheng et al., 2013) 
rs2736108 5p15.33 TERT C/T 0.28 0.98 0.21 0.18 0.23 1.03 0.88 1.19 0.73 1.05 0.87 1.26 0.61 
(Bojesen et al., 
2013b) 
rs3215401 5p15.33 TERT  - /C 0.34 0.97 0.22 0.19 0.24 1.03 0.89 1.20 0.68 1.06 0.89 1.27 0.52 
(Bojesen et al., 
2013b) 
rs2242652 5p15.33 TERT G/A 0.20 1.04 0.14 0.12 0.16 1.15 0.97 1.37 0.11 1.02 0.83 1.25 0.87 
(Bojesen et al., 
2013b) 
rs889312 5q11.2 MAP3K1 C/A 0.48 0.95 0.57 0.54 0.60 1.03 0.90 1.14 0.67 0.87 0.69 1.03 0.12 (Zheng et al., 2013) 
rs1353747 5q11.2 PDE4D T/G 
 
1.18 0.11 0.09 0.13 0.94 0.78 1.13 0.51 1.00 0.80 1.26 0.97 (Zheng et al., 2013) 
rs10472076 5q11.2 RAB3C T/C 0.27 1.02 0.28 0.26 0.31 1.12 0.98 1.28 0.10 1.06 0.91 1.24 0.47 (Zheng et al., 2013) 
rs1432679 5q33.3 EBF1 C/T 0.34 0.92 0.38 0.35 0.41 0.92 0.80 1.04 0.18 0.88 0.75 1.03 0.10 (Zheng et al., 2013) 




rs11242675 6p25.3 FOXQ1 C/T 0.48 0.99 0.51 0.48 0.54 1.06 0.93 1.16 0.35 1.05 0.90 1.17 0.52 (Zheng et al., 2013) 
rs17530068 6q14.1 FAM46A A/G 0.22 
 
0.25 0.23 0.28 1.08 0.94 1.24 0.31 1.01 0.85 1.19 0.93 (Wen et al., 2016) 
rs2046210 6q25.1 ESR1/CCDC170 G/A 0.34 1.27 0.26 0.24 0.29 1.18 1.03 1.36 0.02 1.30 1.11 1.54 0.002 (Zheng et al., 2013) 
rs720475 7q35 ARHGEF5/NOBOX G/A 0.03 0.98 0.19 0.16 0.21 0.98 0.83 1.14 0.76 0.96 0.79 1.16 0.67 (Zheng et al., 2013) 
rs9693444 8p12 DUSP4 C/A 0.29 1.07 0.28 0.25 0.31 1.00 0.87 1.15 0.97 1.00 0.84 1.18 0.99 (Zheng et al., 2013) 
rs6472903 8q21.11 HNF4G T/G 0.04 0.84 0.07 0.06 0.09 1.23 0.98 1.56 0.07 1.13 0.86 1.50 0.38 (Zheng et al., 2013) 
rs13281615 8q24.21 POU5F1B G/A 0.48 0.97 0.43 0.40 0.46 0.98 0.86 1.11 0.74 1.06 0.91 1.24 0.45 (Zheng et al., 2013) 
rs11780156 8q24.21 PVT1/MYC C/T 0.22 1.00 0.18 0.16 0.21 1.09 0.93 1.28 0.28 1.12 0.93 1.36 0.23 (Zheng et al., 2013) 
rs1011970 9p21.3 CDKN2A/B G/T 0.08 1.06 0.37 0.34 0.40 0.99 0.88 1.13 0.93 1.06 0.92 1.23 0.41 (Zheng et al., 2013) 
rs10816625 9q31.2 KLF4 A/G 0.38 1.12 0.15 0.13 0.17 1.09 0.92 1.29 0.31 1.06 0.87 1.30 0.57 (Orr et al., 2015b) 
rs676256 9q31.2 KLF4 A/G 0.05 0.94 0.32 0.29 0.35 0.96 0.84 1.11 0.61 0.88 0.74 1.03 0.12 (Orr et al., 2015b) 
rs865686 9q31.2 KLF4 T/G 0.07 0.96 0.36 0.33 0.39 0.93 0.82 1.06 0.27 0.91 0.78 1.06 0.22 (Zheng et al., 2013) 
rs10759243 9q31.2 KLF4 C/A 0.42 1.05 0.43 0.40 0.46 1.15 1.01 1.30 0.03 1.18 1.01 1.37 0.03 (Zheng et al., 2013) 
rs11814448 10p12.31 DNAJC1  A/C 0.01 1.08 0.06 0.04 0.07 0.94 0.72 1.22 0.62 1.26 0.92 1.74 0.16 (Zheng et al., 2013) 
rs7072776 10p12.31 MLLT10/DNAJC1  G/A 0.03 1.04 0.37 0.34 0.40 0.98 0.86 1.11 0.71 1.01 0.87 1.18 0.90 (Zheng et al., 2013) 
rs10995190 10q21 ZNF365  G/A 0.02 1.06 0.09 0.07 0.10 0.96 0.77 1.20 0.73 1.03 0.79 1.36 0.81 (Zheng et al., 2013) 
rs704010 10q22.3 ZMZ1  C/T 0.29 1.05 0.44 0.41 0.47 0.98 0.86 1.11 0.72 1.02 0.88 1.18 0.82 (Zheng et al., 2013) 
rs7904519 10q25.2 TCF7L2  A/G 0.04 1.02 0.33 0.30 0.35 1.14 1.00 1.29 0.05 1.12 0.96 1.30 0.16 (Zheng et al., 2013) 
rs11199914 10q26.12 FGFR2 C/T 0.40 0.97 0.43 0.40 0.46 0.79 0.69 0.89 0.0002 0.77 0.66 0.89 0.0007 (Zheng et al., 2013) 
rs35054928 10q26.13 FGFR2 -/C 0.44 1.15 0.39 0.36 0.42 1.20 1.06 1.36 0.005 1.17 1.00 1.35 0.05 (Meyer et al., 2013) 
rs2981579 10q26.13 FGFR2  G/A 0.43 1.16 0.39 0.36 0.42 1.21 1.06 1.37 0.003 1.17 1.00 1.35 0.05 (Meyer et al., 2013) 
rs2981578 10q26.13 FGFR2 T/C 0.49 1.19 0.46 0.43 0.49 1.24 1.10 1.41 0.0005 1.20 1.03 1.38 0.02 (Meyer et al., 2013) 
rs3750817 10q26.13 FGFR2 C/T 0.49 1.225 0.41 0.38 0.44 0.83 0.73 0.94 0.005 0.89 0.76 1.03 0.12 
(Elgazzar et al., 
2012) 
rs11200014 10q26.13 FGFR2 G/A 0.26 1.16 0.36 0.33 0.39 1.14 1.01 1.30 0.03 1.06 0.92 1.23 0.43 
(Easton et al., 
2007b) 
rs2420946 10q26.13 FGFR2 C/T 0.37 1.17 0.39 0.36 0.42 1.17 1.03 1.32 0.02 1.12 0.96 1.30 0.14 
(Easton et al., 
2007b) 
rs3817198 11p15.5 LSP1 T/C 0.13 1.07 0.19 0.16 0.21 1.23 1.06 1.43 0.008 1.14 0.95 1.37 0.15 (Zheng et al., 2013) 
rs614367 11q13.3 MYEOV/CCND1 C/T 0.01 0.71 0.06 0.04 0.07 1.34 1.05 1.73 0.02 1.15 0.85 1.57 0.36 (Zheng et al., 2013) 
rs3903072 11q13.1 CFL1/OVOL1 G/T 0.18 0.98 0.32 0.29 0.35 1.02 0.90 1.17 0.75 0.91 0.78 1.07 0.26 (Zheng et al., 2013) 
rs554219 11q13.3 CCND1 C/G 0.02 1.36 0.94 0.92 0.95 0.60 0.21 0.91 0.008 0.80 0.38 1.11 0.23 





rs11820646 11q24.3 BARX2 C/T 0.44 0.95 0.48 0.45 0.51 0.94 0.83 1.07 0.35 0.89 0.77 1.03 0.13 (Zheng et al., 2013) 
rs12422552 12p13.1 ATF7IP G/C 0.28 1.05 0.23 0.20 0.25 1.06 0.92 1.23 0.40 1.14 0.96 1.36 0.13 (Zheng et al., 2013) 
rs17356907 12q22 NTN4  A/G 0.23 0.93 0.38 0.35 0.41 0.94 0.83 1.07 0.38 0.93 0.80 1.09 0.37 (Zheng et al., 2013) 
rs1292011 12q24.21 MED13L/TBX3 A/G 0.26 0.90 0.41 0.38 0.44 0.96 0.85 1.09 0.55 0.96 0.82 1.11 0.57 (Zheng et al., 2013) 
rs2236007 14q13.3 PAX9 G/A 0.25 0.92 0.15 0.13 0.17 0.88 0.74 1.04 0.13 0.88 0.72 1.08 0.22 (Zheng et al., 2013) 
rs999737 14q24.1 RAD51B  T/C 0.00 1.08 0.86 0.84 0.88 1.06 0.88 1.22 0.49 1.16 0.96 1.32 0.12 (Zheng et al., 2013) 
rs2588809 14q24.1 RAD51B  C/T 0.02 1.06 0.16 0.14 0.18 1.28 1.09 1.51 0.003 1.31 1.07 1.59 0.008 (Zheng et al., 2013) 
rs941764 14q32.11 CCDC88C A/G 0.14 1.05 0.42 0.39 0.45 1.21 1.06 1.37 0.004 1.26 1.08 1.46 0.003 (Zheng et al., 2013) 
rs17817449 16q12.2 FTO  T/G 0.12 0.92 0.27 0.24 0.30 0.99 0.86 1.14 0.89 0.93 0.79 1.10 0.41 (Zheng et al., 2013) 
rs11075995 16q12.2 FTO T/A 0.30 1.034 0.36 0.33 0.39 0.95 0.84 1.08 0.41 0.99 0.85 1.15 0.86 
(Garcia-Closas et 
al., 2013b) 
rs3803662 16q12.1 TOX3 A/G 0.36 0.87 0.57 0.54 0.60 0.79 0.63 0,93 0.003 0.70 0.49 0.88 0.0007 (Zheng et al., 2013) 
rs4784227 16q12.1 TOX3 C/T 0.24 1.24 0.35 0.32 0.38 1.21 1.07 1.38 0.003 1.20 1.03 1.40 0.02 (Zheng et al., 2013) 
rs13329835 16q23.2 CDYL2  A/G 0.05 1.02 0.17 0.15 0.20 1.22 1.04 1.43 0.02 1.23 1.02 1.49 0.03 (Zheng et al., 2013) 
rs6504950 17q22 STXBP4 G/A 0.07 0.98 0.17 0.15 0.20 1.17 1.00 1.37 0.05 1.14 0.95 1.37 0.17 (Zheng et al., 2013) 
rs1436904 18q11.2 CHST9  T/G 0.45 0.98 0.45 0.42 0.48 0.87 0.76 0.98 0.02 0.90 0.78 1.05 0.18 (Zheng et al., 2013) 
rs527616 18q11.2 AQP4 G/C 0.31 0.97 0.74 0.71 0.77 0.94 0.78 1.08 0.40 0.99 0.80 1.14 0.88 (Zheng et al., 2013) 
rs8170 19p13.11 BABAM1=MERIT40  G/A 0.01 
 
0.09 0.08 0.11 1.16 0.95 1.43 0.15 1.07 0.84 1.37 0.58 (Zheng et al., 2013) 
rs2363956 19p13.11 ANKLE1 A/C 0.32 
 
0.40 0.37 0.43 1.05 0.93 1.19 0.42 1.06 0.91 1.23 0.48 (Wen et al., 2016) 
rs4808801 19p13.11 ELL A/G 0.25 0.96 0.32 0.29 0.35 0.96 0.84 1.10 0.59 0.95 0.81 1.11 0.51 (Zheng et al., 2013) 
rs3760982 19q13.31 KCNN4/LYPD5 G/A 0.13 1.02 0.31 0.28 0.34 1.14 1.00 1.29 0.06 1.09 0.93 1.27 0.29 (Zheng et al., 2013) 
rs2284378 20q11.22 RALY  C/T 0.26 1.08 0.32 0.29 0.35 1.04 0.92 1.19 0.52 1.00 0.85 1.17 0.99 (Siddiq et al., 2012) 
rs2823093 21q21.1 NRIP1  G/A 0.03 0.93 0.32 0.29 0.34 0.77 0.67 0.89 0.0003 0.84 0.71 0.99 0.04 (Zheng et al., 2013) 
rs6001930 22q13.1 MKL1 T/C 0.28 1.03 0.11 0.09 0.13 0.99 0.81 1.20 0.92 0.96 0.76 1.21 0.73 (Zheng et al., 2013) 
Abbreviations: MAF, minor allele frequency; AF, allele frequency; OR, odds ratio; adj., adjusted; CI, confidence interval. 
* Genome assembly GRCh37. 
1AFs and ORs different in Asia and Colombia (non-overlapping confidence intervals) are marked in bold. 
2P values smaller than 0.05 are marked in bold, P values smaller than 0.05 after multiplicity adjustment using multiple permutation are underlined. 
3OR adjusted for age, family history of breast cancer in first-degree female relatives, oral contraceptive use, menopausal status combined with postmenopausal hormone therapy 







Table S4: Associations between 78 previously known risk SNPs in the Colombian 
population by estrogen receptor status 
 
ER-positive (N=592) ER-negative (N=170) 
SNP ID Locus 
Gene/nearest 
gene(s)*  ORadj.1 95% CI P-value2 ORadj.1 95% CI P-value2 
rs11249433 1p11.2 EMBP1 0.99 0.82 1.19 0.92 0.94 0.70 1.25 0.66 
rs11552449 1p13.2 DCLRE1B 0.89 0.74 1.06 0.20 0.97 0.74 1.27 0.84 
rs616488 1p36.22 PEX14  0.92 0.77 1.10 0.35 0.82 0.62 1.09 0.17 
rs6678914 1q32.1 LGR6  1.15 0.96 1.38 0.13 0.98 0.72 1.32 0.88 
rs4245739 1q32.1 MDM4  1.00 0.82 1.22 0.99 0.96 0.70 1.30 0.79 
rs12710696 2p24.1 OSR1 1.03 0.85 1.24 0.77 0.79 0.58 1.07 0.13 
rs4849887 2q14.1 INHBB 0.81 0.61 1.08 0.16 0.80 0.49 1.24 0.33 
rs1550623 2q31.1 CDCA7 0.97 0.79 1.20 0.79 1.04 0.75 1.43 0.80 
rs2016394 2q31.1 DLX2 0.97 0.82 1.15 0.74 0.80 0.61 1.04 0.09 
rs16857609 2q35 DIRC3 0.91 0.76 1.10 0.34 0.87 0.66 1.15 0.35 
rs4442975 2q35 IGFBP5 1.16 0.98 1.39 0.09 1.17 0.89 1.53 0.26 
rs4973768 3p24.1 SLC4A7 0.95 0.79 1.13 0.54 0.96 0.73 1.26 0.76 
rs12493607 3p24.1 TGFBR2 0.88 0.73 1.07 0.19 0.98 0.73 1.32 0.91 
rs6762644 3p26.1 EGOT/ITPR1 1.03 0.86 1.24 0.75 1.48 1.12 1.94 0.005 
rs9790517 4q24 TET2 0.96 0.80 1.15 0.66 1.05 0.79 1.40 0.71 
rs6828523 4q34.1 ADAM29 0.94 0.75 1.18 0.60 0.87 0.60 1.23 0.43 
rs10941679 5p12 MRPS30 1.14 0.94 1.37 0.18 0.99 0.74 1.31 0.93 
rs10069690 5p15.33 TERT 1.01 0.83 1.24 0.91 1.22 0.91 1.63 0.18 
rs2736108 5p15.33 TERT 1.08 0.87 1.33 0.50 0.89 0.63 1.23 0.49 
rs3215401 5p15.33 TERT 1.09 0.88 1.34 0.42 0.93 0.67 1.28 0.68 
rs2242652 5p15.33 TERT 1.12 0.89 1.42 0.33 1.18 0.83 1.67 0.35 
rs889312 5q11.2 MAP3K1 1.25 1.05 1.49 0.01 0.85 0.65 1.11 0.24 
rs1353747 5q11.2 PDE4D 0.94 0.72 1.22 0.65 1.13 0.76 1.64 0.53 
rs10472076 5q11.2 RAB3C 1.11 0.92 1.33 0.27 0.83 0.62 1.12 0.24 
rs1432679 5q33.3 EBF1 0.86 0.72 1.03 0.10 1.07 0.81 1.42 0.61 
rs204247 6p23 RANBP9 1.17 0.98 1.39 0.08 0.85 0.65 1.11 0.23 
rs11242675 6p25.3 FOXQ1 0.95 0.80 1.12 0.55 0.83 0.64 1.07 0.16 
rs17530068 6q14.1 FAM46A 0.97 0.80 1.18 0.75 1.27 0.95 1.70 0.10 
rs2046210 6q25.1 ESR1/CCDC170 1.33 1.10 1.61 0.003 1.34 1.00 1.78 0.05 
rs720475 7q35 ARHGEF5/NOBOX 0.84 0.66 1.06 0.14 1.23 0.88 1.71 0.21 
rs9693444 8p12 DUSP4 1.05 0.87 1.28 0.60 0.91 0.67 1.23 0.55 
rs6472903 8q21.11 HNF4G 1.22 0.89 1.68 0.21 1.06 0.64 1.70 0.80 
rs13281615 8q24.21 POU5F1B 1.02 0.85 1.21 0.86 1.09 0.83 1.43 0.55 
rs11780156 8q24.21 PVT1/MYC 1.15 0.92 1.44 0.20 1.08 0.77 1.49 0.67 
rs1011970 9p21.3 CDKN2A/B 1.00 0.84 1.19 0.99 1.38 1.07 1.79 0.01 
rs10816625 9q31.2 KLF4 1.09 0.86 1.37 0.49 1.05 0.73 1.49 0.79 
rs676256 9q31.2 KLF4 0.88 0.73 1.07 0.20 0.82 0.61 1.10 0.19 
rs865686 9q31.2 KLF4 0.89 0.74 1.07 0.21 0.85 0.65 1.11 0.25 
rs10759243 9q31.2 KLF4 1.18 0.99 1.41 0.06 1.01 0.77 1.32 0.94 
rs11814448 10p12.31 DNAJC1  1.11 0.75 1.63 0.61 1.35 0.74 2.33 0.30 
rs7072776 10p12.31 MLLT10/DNAJC1  0.99 0.83 1.18 0.91 1.10 0.84 1.43 0.50 
rs10995190 10q21 ZNF365  1.07 0.78 1.47 0.67 0.88 0.51 1.43 0.61 
rs704010 10q22.3 ZMZ1  1.03 0.87 1.23 0.71 0.95 0.73 1.23 0.68 
rs7904519 10q25.2 TCF7L2  1.03 0.86 1.23 0.78 1.01 0.77 1.33 0.92 
rs11199914 10q26.12 FGFR2 0.74 0.62 0.89 0.001 0.75 0.57 0.99 0.04 
rs35054928 10q26.13 FGFR2 1.20 1.01 1.43 0.04 1.23 0.94 1.61 0.13 




rs2981578 10q26.13 FGFR2 1.24 1.05 1.48 0.01 1.27 0.98 1.65 0.07 
rs3750817 10q26.13 FGFR2 0.91 0.76 1.08 0.27 0.80 0.61 1.06 0.12 
rs11200014 10q26.13 FGFR2 1.10 0.93 1.31 0.28 1.09 0.84 1.42 0.51 
rs2420946 10q26.13 FGFR2 1.16 0.97 1.38 0.10 1.24 0.95 1.61 0.11 
rs3817198 11p15.5 LSP1 1.19 0.97 1.46 0.09 1.09 0.78 1.50 0.60 
rs614367 11q13.3 MYEOV/CCND1 1.06 0.73 1.51 0.77 1.44 0.85 2.35 0.16 
rs3903072 11q13.1 CFL1/OVOL1 0.86 0.72 1.04 0.12 1.05 0.79 1.39 0.73 
rs554219 11q13.3 CCND1 1.14 0.80 1.61 0.46 1.21 0.71 1.99 0.47 
rs11820646 11q24.3 BARX2 0.90 0.76 1.07 0.23 0.91 0.70 1.18 0.47 
rs12422552 12p13.1 ATF7IP 1.13 0.92 1.39 0.24 0.97 0.69 1.33 0.83 
rs17356907 12q22 NTN4  0.86 0.72 1.02 0.09 1.08 0.83 1.41 0.56 
rs1292011 12q24.21 MED13L/TBX3 1.02 0.86 1.22 0.80 1.03 0.78 1.34 0.85 
rs2236007 14q13.3 PAX9 0.90 0.71 1.13 0.36 1.04 0.73 1.46 0.83 
rs999737 14q24.1 RAD51B  0.79 0.61 1.01 0.07 0.79 0.52 1.16 0.24 
rs2588809 14q24.1 RAD51B  1.28 1.01 1.61 0.04 1.16 0.81 1.64 0.40 
rs941764 14q32.11 CCDC88C 1.30 1.09 1.55 0.004 1.42 1.08 1.86 0.01 
rs17817449 16q12.2 FTO  0.91 0.75 1.11 0.36 0.93 0.68 1.25 0.63 
rs11075995 16q12.2 FTO 0.99 0.82 1.18 0.89 0.94 0.71 1.23 0.63 
rs3803662 16q12.1 TOX3 1.33 1.12 1.58 0.001 1.06 0.80 1.38 0.70 
rs4784227 16q12.1 TOX3 1.25 1.05 1.49 0.01 1.06 0.81 1.40 0.67 
rs13329835 16q23.2 CDYL2  1.20 0.96 1.49 0.11 1.34 0.98 1.82 0.07 
rs6504950 17q22 STXBP4 0.99 0.80 1.23 0.95 1.46 1.08 1.98 0.01 
rs1436904 18q11.2 CHST9  0.92 0.77 1.10 0.38 1.05 0.80 1.36 0.74 
rs527616 18q11.2 AQP4 0.99 0.82 1.21 0.95 1.13 0.84 1.51 0.41 
rs8170 19p13.11 BABAM1=MERIT40  1.02 0.76 1.36 0.91 1.39 0.92 2.06 0.11 
rs2363956 19p13.11 ANKLE1 1.09 0.92 1.30 0.32 0.87 0.66 1.14 0.31 
rs4808801 19p13.11 ELL 1.04 0.86 1.26 0.67 0.80 0.60 1.06 0.13 
rs3760982 19q13.31 KCNN4/LYPD5 1.10 0.92 1.33 0.29 1.15 0.87 1.52 0.33 
rs2284378 20q11.22 RALY  1.06 0.88 1.27 0.55 1.08 0.81 1.41 0.60 
rs2823093 21q21.1 NRIP1  0.73 0.60 0.89 0.002 0.94 0.70 1.26 0.69 
rs6001930 22q13.1 MKL1 0.93 0.71 1.22 0.62 0.91 0.58 1.37 0.66 
Abbreviations: OR, odds ratio; adj., adjusted; CI, confidence interval. 
*Genome assembly GRCh37. 
1OR adjusted for age, family history of breast cancer in first-degree female relatives, oral contraceptive 
use, menopausal status combined with postmenopausal hormone therapy use, body mass index, 
smoking status, parity, age at first full-term pregnancy, age at menarche, and breastfeeding. 





Table S5: Assessment of potential interaction between 13 significant SNPs in the Colombian population and European ancestry 
    
Group of women according to quartiles of European ancestry  
(ancestry ranges, N cases, N controls) 
   
Interaction 0-45.0%, 218, 243 45.1%-55.0%, 225, 235 55.1%-66.0%, 231, 229 66.1%-100%, 315, 146 
SNP ID Locus 
Gene/nearest 
gene(s)*  P-value1 ORadj.2 95% CI ORadj.2 95% CI ORadj.2 95% CI ORadj.2 95% CI 
rs4442975 2q35 IGFBP5 0.23 1.34 0.95 1.91 0.91 0.65 1.28 1.42 1.03 1.98 1.02 0.72 1.44 
rs2046210 6q25.1 ESR1/CCDC170 0.96 1.08 0.75 1.57 1.64 1.13 2.38 1.07 0.75 1.51 1.31 0.90 1.92 
rs10759243 9q31.2 KLF4 0.84 1.13 0.82 1.57 1.34 0.99 1.84 0.96 0.69 1.35 1.43 1.01 2.06 
rs11199914 10q26.12 FGFR2 0.99 0.71 0.51 0.99 0.81 0.59 1.11 0.84 0.60 1.17 0.79 0.54 1.13 
rs35054928 10q26.13 FGFR2 0.51 1.46 1.04 2.05 1.14 0.85 1.54 0.98 0.71 1.37 1.13 0.79 1.64 
rs2981579 10q26.13 FGFR2 0.39 1.43 1.02 2.01 1.18 0.88 1.60 0.98 0.71 1.36 1.06 0.74 1.53 
rs2981578 10q26.13 FGFR2 0.53 1.44 1.04 2.00 1.19 0.89 1.59 1.11 0.80 1.54 1.12 0.79 1.61 
rs2588809 14q24.1 RAD51B 0.40 1.15 0.73 1.80 1.58 1.03 2.45 1.42 0.93 2.21 1.18 0.74 1.92 
rs941764 14q32.11 CCDC88C 0.02 0.91 0.65 1.27 1.29 0.94 1.78 1.63 1.18 2.27 1.76 1.23 2.56 
rs3803662 16q12.1 TOX3 0.03 1.32 0.96 1.84 1.46 1.06 2.04 1.35 0.99 1.85 1.07 0.74 1.56 
rs4784227 16q12.1 TOX3 0.32 1.05 0.76 1.44 1.35 0.98 1.86 1.41 1.03 1.93 0.88 0.59 1.30 
rs13329835 16q23.2 CDYL2 0.24 1.04 0.71 1.51 0.94 0.63 1.40 1.17 0.73 1.89 1.86 1.16 3.05 
rs2823093 21q21.1 NRIP1 0.58 0.78 0.54 1.12 0.97 0.68 1.38 0.85 0.60 1.19 0.78 0.51 1.19 
Abbreviations: OR, odds ratio; adj., adjusted; CI, confidence interval. 
*Genome assembly GRCh37. 
1P-values smaller than 0.05 are marked in bold. 
2OR adjusted for age, family history of breast cancer in first-degree female relatives, oral contraceptive use, menopausal status combined with postmenopausal 





Table S6: Assessment of potential interaction between 13 significant SNPs in the Colombian population and Native American 
ancestry 
    
Group of women according to quartiles of Native American ancestry  
(ancestry ranges, N cases, N controls) 
   
Interaction 0-27.0%, 326, 135 27.1%-38.0%, 242, 218 38.1%-47.0%, 207, 253 47.1%-100%,214, 247 
SNP ID Locus 
Gene/nearest 
gene(s)*  P-value1 ORadj.2 95% CI ORadj.2 95% CI ORadj.2 95% CI ORadj.2 95% CI 
rs4442975 2q35 IGFBP5 0.37 1.18 0.83 1.69 1.22 0.88 1.69 1.09 0.79 1.52 1.10 0.77 1.57 
rs2046210 6q25.1 ESR1/CCDC170 0.66 1.25 0.86 1.84 1.42 1.00 2.03 1.18 0.82 1.69 1.20 0.82 1.77 
rs10759243 9q31.2 KLF4 0.91 1.53 1.06 2.22 1.09 0.78 1.51 1.11 0.79 1.55 1.27 0.92 1.75 
rs11199914 10q26.12 FGFR2 0.58 0.89 0.61 1.29 0.77 0.55 1.06 0.82 0.60 1.13 0.66 0.47 0.91 
rs35054928 10q26.13 FGFR2 0.69 1.06 0.73 1.54 1.00 0.72 1.40 1.19 0.86 1.65 1.27 0.92 1.76 
rs2981579 10q26.13 FGFR2  0.75 0.95 0.66 1.37 1.06 0.76 1.48 1.21 0.87 1.67 1.26 0.91 1.74 
rs2981578 10q26.13 FGFR2 0.68 0.89 0.62 1.29 1.22 0.88 1.69 1.33 0.97 1.84 1.21 0.88 1.67 
rs2588809 14q24.1 RAD51B  0.63 1.48 0.91 2.50 1.33 0.87 2.04 1.62 1.05 2.53 1.09 0.70 1.69 
rs941764 14q32.11 CCDC88C 0.02 1.41 0.98 2.03 1.84 1.31 2.60 1.34 0.98 1.82 0.97 0.68 1.38 
rs3803662 16q12.1 TOX3 0.02 1.13 0.77 1.65 1.25 0.91 1.73 1.61 1.17 2.24 1.42 1.02 1.99 
rs4784227 16q12.1 TOX3 0.25 1.02 0.68 1.53 1.19 0.87 1.65 1.54 1.12 2.14 1.11 0.80 1.53 
rs13329835 16q23.2 CDYL2  0.98 1.16 0.77 1.77 1.40 0.89 2.22 0.83 0.54 1.25 1.24 0.81 1.91 
rs2823093 21q21.1 NRIP1  0.68 0.84 0.57 1.25 0.80 0.56 1.14 0.84 0.59 1.19 0.99 0.68 1.43 
Abbreviations: OR, odds ratio; adj., adjusted; CI, confidence interval. 
*Genome assembly GRCh37. 
1P-values smaller than 0.05 are marked in bold. 
2OR adjusted for age, family history of breast cancer in first-degree female relatives, oral contraceptive use, menopausal status combined with postmenopausal 
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